¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/10 ¤W¤È 07:53:50
²Ä 5783 ½g¦^À³
|
³¯¤j¡B whalewisdom.com/stock/asln «ùªÑ1000¤dªÑªº¤jªÑªFªk¤H¦³7Ó¤½¥q¡D
¥L̪º¸g²z¤H·|©MASLN¤½¥q°µ¹Hªkªº ¤º½u¥æ©ö?
¤£·|¨º»ò儍! ¦D¨Æ/¥Á¨Æ½ßÀv¦b¬ü½ß¤j¤F¡D
¦óªp¥¼¸Ñª¼¹ê¦bµL¥¿½T¼Æ¾Ú¥i¨Ñ¤º½u!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/12/9 ¤U¤È 11:44:01
²Ä 5782 ½g¦^À³
|
³o®a¤½¥q¨C¦¸°Ñ¥[°ê»Ú·|ij«á¡A
©ÎªÌ¤½¥¬¸Ñª¼°T®§¡A±q¨S¦n¨Æµo¥Í¹L¡AªÑ»ù±q¥¼¥¿±¤ÏÀ³¡A³£¬O«æ¶^©Î¬O½w¶^«ùÄò¶^¡A·Pı¬OÓªÅÀY¤½¥q¡ACEO ´N¬O¥Ö¥]²Õ¶RªÅ½æªÅªº¡A
004 2bªì¨Bªº´Á¤¤¼Æ¾Ú¦pªG¤£¿ù¡A
ì©l¤jªÑªF¤@©w·|¥ýª¾¹D¡AªÑ»ù¤S¦b¾ú¥vªº§CÀÉ¡A¤jªÑªF̲@µL§@¬°¡AµL¥ô¦óÅ@½L°Ê§@¡A´N¬O¹ï¤½¥q²@µL«H¤ß¡A
§Ú¹ï¤½¥q¤]¤£©ê§Æ±æ¡A´N·í¶R¼Ö³z¡A¥á¨ì¯ä¤ô·¾¸Ì¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/8 ¤W¤È 06:48:13
²Ä 5781 ½g¦^À³
|
Aslan004 2b ²q´ú¤Î´Á±æ¡G¨Ì¾ÚDupilumab¤ÎLebrikizumab 2b,ASLAN004 1b 1.400mg/Q2W EASI75 69% IGA0,1 53%
2.400mg/Q4W EASI75=69%*93%=64% IGA0,1=53%*75%=40% IGA0,1Àø®Ä²q´ú 400mg/Q2w//53%>300mg/Q2W//49%> 600mg/Q4W//47%>400mg/Q4W//40%> ¹ï·Ó组15% ,¥¼¸Ñª¼¥H¤W¥§¡40%.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/12/6 ¤U¤È 04:47:29
²Ä 5780 ½g¦^À³
|
¤½¥q¦U¤½§i¦¨¥ß¦¬®×¤¤¤ß®É¶¡ÂI¡A©¹«á±À¦ô¤½§i¸Ñª¼¼Æ¾Ú®É¶¡¡G 1.05/06¤½§i¦¨¥ß36Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A111/12/06¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C
2.06/28¤½§i¦¨¥ß39Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/01/28¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C
3.07/13¤½§i¦¨¥ß42Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/02/13¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C
4.07/15¤½§i¦¨¥ß43Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/02/15¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C
5.08/01¤½§i¦¨¥ß45Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/03/01¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C
6.08/23¤½§i¦¨¥ß65Ó©Û¶Ò(¦¬®×)¤¤¤ß¡A¥[2Ó¤ë©Û¶Ò(¿z¿ï)¡A¥[4Ó¤ëªvÀø(¸ÕÅç)¡A¥[1Ó¤ë¼Æ¾Ú¾ã²z¡A112/03/23¥H«á¤½¥¬¸Ñª¼¼Æ¾Ú¡C (¨Ñ°Ñ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/12/6 ¤U¤È 12:44:01
²Ä 5779 ½g¦^À³
|
´£¿ô¡G ¤µ¦~5¤ë6¤é¡A¤½¥q¤½§i¤w¶}¹F36Ó©Û¶Ò¤¤¤ß(¶W¹L´Á¤¤´¦ÅS©Ò»Ý±ø¥ó)¡A °²³]¥Î2Ó¤ë¨Ó©Û¶Ò(¿z¿ï)¡A§Y7¤ë6¤é¶}©lªvÀø¡C
¦A¥Î4Ó¤ëªvÀø¡A«h11¤ë6¤éªº16¶gªvÀø§¹¦¨¡C
¦A1Ó¤ë¸ê®Æ¾ã²z¡A¤]´N¬O¤µ¤Ñ(12¤ë6¤é)¥H«á¥i¥H´¦ÅS´Á¤¤¼Æ¾Ú¡C (ºÞ²z¶¥¼h¤w´x´¤ª¼¼Æ¾Ú)
¦U¦ì¥i¥H¶}©lÆ[¹îªÑ»ùªºªí²{¤F¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/6 ¤W¤È 11:59:43
²Ä 5778 ½g¦^À³
|
¤@¡BLebrikizumab 2b ¤¤-«¯gAD x16¶gªvÀø
www.clinicaltrials.gov/ct2/show/results/NCT03443024
125mg-Q4W//250mg-Q4W//250mg-Q2W//¹ï·Ó²Õ
1.EASI 75¡]%¡^ 43.3//56.1//60.6//24.3
2.IGA0,1¡]%¡^ 26.6//33.7//44.6//15.3
¨C¥|¶g¤@°w¤@250mg vs ¨C2¶g¤@°w250mg 1.EASI75 56.1/60.6=93% 2.IGA0,1 33.7/44.6=76%
Lebrikizumab 2b ªº¥|¶g¤@°w¦bEASI75ªºÀø®Ä¬°¤G¶g¤@°w93%¡]«e16¶gªvÀø¡^ Lebrikizumab 2b ªº¥|¶g¤@°w¦bIGA0,1ªºÀø®Ä¥u¦³¤G¶g¤@°wªº75%¡C¡]«e16¶gªvÀø¡^
¤@¤@¤@Lebrikizumab ph3 17¡ã52¶gªvÀø.¦b4¶g¤Î2¶gEASI75&IGA0,1Àø®Ä®t¤£¦h¡C
¤G¡BDupilumab 2b ¥|¶g¤@°w vs ¤G¶g¤@°w
www.clinicaltrials.gov/ct2/show/results/NCT01859988
300mg-Q4W//300mgQ-2W//¤ñ²v 1.EASI75 49.2%//53.1%//93% 2.IGA0,1 21.5%///29.7%//74%
¤T¡AASLAN004 2b ¥|¶g¤@°w vs ¤G¶g¤@°w ªºÀø®Ä®t²§¡H¡H¡H
¤]³\±µªñ¤WzLebrikizumab 2b¤ÎDupilumab 2b ¥|¶gVs ¤G¶gÀø®Ä®t²§
¦bEASI75 ®t²§93% IGA0,1 ®t²§75%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/3 ¤W¤È 08:05:13
²Ä 5777 ½g¦^À³
|
¥Ö½§¬ìÂå®v¨Ï¥Î¤@ºØ«ÈÆ[ªºµû¦ô¤è¦¡¡GEASIµû¤À¡A¥Î¥Hpºâ²§¦ì¥Ö½§ª¢ªºÄY««×¡FEASI¤À¼Æ¶V°ª¶VÄY«¡CEASI-50¥NªíÄY««×§ïµ½¤@¥b¡BEASI-75¥NªíÄY««×§ïµ½¤C¦¨¤¡A¥H¦¹Ãþ±À¡C
¥H§Ú̪ºÁ{§É¸gÅç¡A 1.¹F¨ìEASI-50(ÄY««×°§C¤@¥b)¡A±wªÌ¸ò®aÄÝ´Nı±o®ÄªG«Ü¦n¡A³q±`º¡·N«×´N«Ü°ª¡F 2.¦ÓEASI-75(§ïµ½¤C¦¨¤)·|ı±o®ÄªG«D±`¦n¡Aı±o§ä¹ïÂå¥Í¤F¡A·P¿E®÷¹s¡F
3.EASI-90(§ïµ½¤E¦¨)·|ı±o´X¥G¦n¤F¡A§Ö§âÂå¥Í·í¯«¦b«ô¡CY±NªvÀø®ÄªG¶q¤Æ¡G
www.dr-skin.com.tw/health/view/240 ²§¦ì©Ê¥Ö½§ª¢¼Ð¹vÃĪ«¡u§ùÁת¢¡v¡GÀø®Ä¡B°Æ§@¥Î¡B¨Ï¥Î¤è¦¡¡B¶O¥Î¸ÑªR |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/12/2 ¤U¤È 08:34:16
²Ä 5776 ½g¦^À³
|
³¯¤j¡A§Ú¤]»{¬°¤w¦³50%¥H¤Wªº16¶g¸ÕÅç¤w§¹¦¨¡A¦ý¥HªÑ»ùªºªí²{¨Ó¬Ý¡AÁ٬ݤ£¥Xª¼¼Æ¾Ú¦³¦n¨ìn¤jº¦ªº¸ñ¶H~Ó¤H§PÂ_¡A¤£·íªÑ²¼¶i¥Xªº°Ñ¦Ò~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/2 ¤U¤È 12:11:35
²Ä 5775 ½g¦^À³
|
³¯¤j¡A ASLN ¤½¥qÀ³¸Ó¥u¦³¥¼¸Ñª¼ªº¼Æ¾Ú¡C
¦p¸ó±i¤j©Ò¦ô¡A¦Ü¤Ö¦³¬ù50%§¹¦¨16¶gªvÀø¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/12/2 ¤W¤È 10:57:19
²Ä 5774 ½g¦^À³
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/12/2 ¤W¤È 06:32:10 ¬Q±ß¶È¨Ñ¿ýµÀÉ¡D¥i¤Wºô¤U¸ü¡D¨ä¥L¦p11¤ë²³ø¤º®e¡D¥D«ù¤H°Ý¨ìASLAN004¤T´Á·Ç³Æ¡Bµª¡G±N¬O400¤HªºÁ{§É
´£¿ô¡G 1.¤]´N¬O2b Á{§É´Á¤¤¼Æ¾Ú¸g¤½¥q¤º³¡½T»{¬O¥¿¦VµL»~¡A¤~·|³Q°Ý¨ìASLAN004n°µ¤T´Á·Ç³Æ¡C
2.¤µ¦~5¤ë6¤é¡A¤½¥q¤½§i¤w¶}¹F36Ó©Û¶Ò¤¤¤ß¡A°²³]¥Î2Ó¤ë¨Ó©Û¶Ò(¿z¿ï)¡A§Y7¤ë6¤é¶}©lªvÀø¡C¦A¥Î4Ó¤ëªvÀø¡A«h11¤ë6¤éªº16¶gªvÀø§¹¦¨¡C¦A1Ó¤ë¸ê®Æ¾ã²z¡A 12¤ë6¤é¥H«á¥i¥H´¦ÅS´Á¤¤¼Æ¾Ú¡C(¦ý¡A¬Ý¨Ó¡A´Á¤¤³ø§i¼Æ¾Ú´£«e1¬P´Á¥X¨Ó¤F)
(ºÞ²z¶¥¼h¤wª¾¹D´Á¤¤¼Æ¾Ú¤º®e¡A¥D«ù¤H¤~·|°Ý¤T´Á·Ç³Æ°ÝÃD) ¦U¦ì¥i¥H¶}©lÆ[¹îªÑ»ùªºªí²{¤F¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/12/2 ¤W¤È 10:56:55
²Ä 5773 ½g¦^À³
|
¤Ñ©R¤j
¨È·à±d004¤T´Á¡A¬°400¤HÁ{§É°µ·Ç³Æ
¬O§_¥Nªí2´ÁÁ{§É¤wµL°ÝÃD¶Ü
¥i¯à·|¦³2´Á´Á¤¤³ø§i¶Ü¡A¸Ñ¨MªÑ»ùªø´Á§C©ó1¬ü¤¸¦M¾÷
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/2 ¤W¤È 06:32:10
²Ä 5772 ½g¦^À³
|
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference
¬Q±ß¶È¨Ñ¿ýµÀÉ¡D¥i¤Wºô¤U¸ü¡D ¨ä¥L¦p11¤ë²³ø¤º®e¡D
¥D®u¤H°Ý¨ìASLAN004¤T´Á·Ç³Æ¡B µª¡G±N¬O400¤HªºÁ{§É (Ó¤H¸É¥R¡G¤@¯ë¬O2Ó¤T´ÁÁ{§É¡B¥B¥[52¶gªº©µªø¹êÅç¡B¥t¥i¯à°l¥[¤QTCS¥~¥ÎÃÄ»I¤@Ãþ©T¾J¤T´ÁÁ{§É¡B¥H¦¹¥Ó½Ð¬ü°êªºÃĵý)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2022/11/22 ¤U¤È 06:09:40
²Ä 5771 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/11/22 ¤U¤È 03:42:05
²Ä 5770 ½g¦^À³
|
¤½¥q©ó5¤ë6¤é¤½¥¬²Ö¿n36Ó¦¬®×¤¤¤ß¦¨¥ß(¶W¹L´Á¤¤³ø§i´¦ÅS©Ò»Ýn¥ó)¡A °²Y©ó6¤ë20¤é¦¬º¡¸ÕÅçªÌ¨Ã¶}©lªvÀø¡A ¸g4Ó¤ëªvÀø«á§Y¬O10¤ë20¤é¡A ¦A1Ó¤ë¸ê®Æ¾ã²z§Y¬O11¤ë20¤é¡C ¬Q¤Ñ(11/21)¤½¥q¤½§i±N¦b¯Ã¬ù°Ñ¥[ÂåÀø«O°··|ij(11/29~12/1)¡C (¤£n´Á«Ý¤Ó²`¡A¦]¥u¦³CEO¥h)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/11/22 ¤W¤È 09:04:23
²Ä 5769 ½g¦^À³
|
±aÓ004´Á¤¤¼Æ¾Ú¡A©Î¬Oª¼¼Æ¾Ú¤]¦n¡AÅý¥«³õ¤ÀªR®v±M®aÀ°§A»{ÃÒ¡A¦Ñ·à¤~¦³¾÷·|¥XÀY¤Ñ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/21 ¤U¤È 08:54:59
²Ä 5768 ½g¦^À³
|
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference
SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET. The conference will be held from November 29 to December 1, 2022, in-person at the Lotte New York Palace Hotel, New York, NY.
A replay of the fireside chat will be made available on the Investor Relations section of ASLAN¡¦s website and can be accessed directly at this link.
Management will be available for one-on-one meetings with investors throughout the conference. Please contact your representative at Piper Sandler to schedule a meeting. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/20 ¤W¤È 10:27:49
²Ä 5767 ½g¦^À³
|
ASLAN 2b¼ÒÀÀ(¸É¥R) ²Ä0¤Ñ EASI28 ²Ä21¤Ñ ¹êÅç组¥§¡EASI=14¤À(°50%¡^ ¹ï·Ó组¥§¡EASI=25¤À(°12%)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/18 ¤U¤È 03:20:15
²Ä 5766 ½g¦^À³
|
Æ[¹î¤G¡C
www.nejm.org/doi/full/10.1056/nejmoa1610020 Dupilumab 2Ó¤T´ÁÁ{§É¡A¹Ï¤G¡A¦U¶gEASI¤U°Àø®ÄÁͶչϡC
¹ï·Ó²Õ¥u¥´¦w衞¾¯ªº±wªÌ¡C
¦b²Ä¤T¶gªºÀø®Ä¬ù12¡ã15%¡A¤§«á«ùÄò¤U°¦Ü12¶g33%¡C¡]¥´¦w¥þ衞¾¯ªÌ¥ç¦³AD¦Û¡¯à¤O¡A¦¹´Á¶¡°20%¡ã18%¡^
¦Ó¥´Dupilumabªº²Õ¤£ºÞ¨C¶g¤@°w©Î¤G°w¡A¦b²Ä¤T¶gÀø®Ä¤w¤U°¦Ü45¡ã50%EASI ²Ä¤Q¤G¶g¨£©³ÂI¥§¡¬ù°¦Ü70%¡C¡]¦¹´Á¶¡¶È°70%¤@45¡ã50%=25%~20%)
¦b²Ä¤T¶g®É¥´Dupilumab¬Û¹ï©ó¥´¦w衞¾¯²Õ¯f±¡§ó»´¬ù35%±j¡A©Ò¥H¦Û¡¯à¤O²zÀ³¤j©ó¦w衞¾¯²Õ¡C
ASLAN004 2b«e¤T¾¯¥i§¹¥þ§í¨îIL/IL4¨ì²Ä21¤é¡A¤§«á¦³22¡ã27¤é¥i¯àµL§¹¥þ§í¨îª¬ªp¡A¦ý¤´°ª©ó¦w衞¾¯²Õªº¦Û¡¯à¤O¥i¯à¡C µ¥²Ä28¤é¥´²Ä¥|°w´N°¨¤W§Î¦¨§¹¥þ§í¨î¤F¡C
Æ[¹î¤T¡C
¦pASLN004ªº´Á¥ZµoªílbX8¶gªvÀø ¥Íª««ü¼Ð¦b²Ä¤T¶gTRAC¤x°¦Ü¬Û¹ï§C¤ô·Ç¡C TRAC¹ï©ó©MEASI¤U°ÁͶլO¥¿¬ÛÃöªº»â¥ý«ü¼Ð¡C
ªñ²Ä¤K¶g¤§¤ô凖¡A²Ä7¡ã11¶g¥¼¥´°w¡A¤´«O¦³§C¤ô¥ªºTRAC¡C
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c P¡A26
¥H¤W¬OÆ[¹î¤Î±À²z¦Ó¨Ó¡C¹ê»Ú¤´«Ý2b¸Ñª¼¤èª¾¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/17 ¤U¤È 03:40:24
²Ä 5765 ½g¦^À³
|
www.nejm.org/doi/10.1056/NEJMoa1314768 ¹Ï¤@¡ADupilumab ¦´Á
EASI50
75mg vs 150mg vs300mg vs¹ï·Ó²Õ x¨C¶g¤@°wx4¶g
¥Ñ¹Ï¤@¥iÆ[¹î¨ì¡A²Ä30¤ÑªºÀø®Ä 300mg >150mg>75mg>¹ï·Ó²Õ
¨ä¤¤300mg/150mg ¦b²Ä15¤éªºpÈ´N¤p©ó0¡P05 ²Îp¤Wªº©úÅã®t²§¡C
75mg/150mg ¨C¶gÀø®Ä¦H©ó300mgªí¥Ü¡A¾¯¶q¤£¨¬¡AµLªk§¹¥þ«ÊªýI4/IL13¸ê°T¶Ç»¼¡C ¦¹®É¥u¬OÀø®Ä·|»¼©µ¡A¥un°÷ªø®É¶¡ªvÀø¡A§C¾¯¶q²Õ¥i¯à²×±N°l¤W°ª¾¯¶q²Õ¡C
Lebrikizumab ¤]¦³Ãþ¦üª¬ªp¡A©µªøªv¡¨ì52¶g¡BIGA0¡A1·|¦A¼W¥[4%¡ã5%¡C
ASLAN004 0/7/14¤é¦U¤@°w.¥i§¹¥þ§í¨î¨ì21¤é¡AEASI50 ¥i¹F¨ì55%¡A ³o¨Ç¤w¦³¤ÏÀ³ªÌ¦b0¡ã7¤Ñªº¥i¯à¤£¨¬¾¯¶q´Á¶¡¡AÄ~Äò´î±Ó©Îú£½w´î±Ó¡A¤Ï¼u¾÷·|¤£¤j¡C
²Ä4°w¦b28¤é¥´°w«á¡A´î±Ó³t«×´NÀ³¸Ó«ì´_¡C
©Ò¥H004 2b ¥Î16¶gX9°wx2¶g¤@°wÀø®Ä¡A¦ôp>=1b ªºmITT 8¶gÀø®ÄÀ³¸Ó¬O¦X²z±À´ú¡C
¤@¤@.¤@.¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@ 2b ¹w´ÁÀø®Ä¡]°ò缐EASI27.5, IGA=3 65%)¡A¼ÒÀÀ
EASI 75=73%~81% vs 24% (©M¹ï·Ó²Õ®t²§ 49%¡ã57%¡^vs Dupilumab 2b 61% IGA0,1=57%~61%. Vs 15%¡]¡G®t²§ 42%¡ã46%¡^vs Dupilumab 2b 43%
¦©°£¹ï·Ó²Õ®t²§¡A¤´¦³Àu©óDupilumab 2b 30%¥H¤Wªº¾÷·|¡AÀø®Äª½¤ñ¤fªAÃĪ«¡]JAK§í¨î¾¯¤G缐ÃĪ«¡^ªº¥i¯à©Ê¤j¡C
¥H¤WÓ¤H¼ÒÀÀ¡C
¥t¥~Q2 ¬ü°ê¹ïú}°òª÷«ù¦³ASLN ´î¤Ö¬ù1400¤dªÑADR
³Ì¤jªÑªFTang ¸ê¥»§ë¸ê¤½¥q¤´¤p¥[½X100¤dªÑADR
·s¥[©Y²H°¨¿ü«ùªÑ¤£ÅÜ¡C
whalewisdom.com/stock/asln
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/12 ¤U¤È 07:52:46
²Ä 5764 ½g¦^À³
|
Lebrikizumab 2b ¦PÀø®Äªº¹F¦¨³t«×§C©óDupilumab 2a ,¦ý²Ä16¶g¦³¬ÛªñªºÀø®Ä¡C ASLAN004 ¨C¶g¤@°w¡A«e8¶gEASI¤U°Àø®Ä³t«×©MDupilumab¬Ûªñ¡C
¤@¤@¤@¤@
Dupilumab 2a N=110 QWx12¶g Vs Lebrikizumab 2b Q2Wx16¶gN¡×75:52
1¡AEASI50 Dupilumab.//Lebrikizumab ²Ä¤T¶g 55%// ²Ä¥|¶g 65%//52% ²Ä¤¶g 85%¡]¨£°ªÂI¡^// ²Ä¤»¶g 85%// ²Ä¤K¶g 85%//70% ²Ä¤Q¤G¶g85%//81%¡]¨£°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//81%
Dupilumab ¥i¦P®Éªý¾×Âù¼Ð¹vIL4/IL13¡A©Ò¥H¦b²Ä¤¶gEASI50´N¹F°ªÂI85%¦ÓLebrikizumab¥u¯àªýÀÉIL13¤Î³¡¤ÀlL4©Ò¥Hª½¨ì²Ä¤Q¤G¶g¤~¹F81%°ªÂI¡C
¤G¡AEASI75 Dupilumab.//Lebrikizumab
²Ä¥|¶g 35%//30% ²Ä¤K¶g ¡X//42% ²Ä¤Q¤G¶g62%//62%¡]°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//61%
¤T¡BIGA 0,1 Dupilumab.//Lebrikizumab
²Ä¥|¶g 18%//18% ²Ä¤K¶g ¤@¤@//30% ²Ä¤Q¤G¶g40%//41% ²Ä¤Q¤»¶g¡X¡X//43%¡]°ªÂI¡^ Lebrikizumab ªý¾×°T®§¯à¤O®Ä¯à¸û®t¡A¦ý®É¶¡©Ôªø¨ì16¶g¡A¤´¥i¸É¨¬IGA0,1ªºÀø®Ä¡C
www.nejm.org/doi/10.1056/NEJMoa1314768 ¹Ï¤@ Dupilumab
www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg
¹Ï¤G¡þªí¤G Lebrikizumab
¤T¡BDupilumab ¤T´Á vs ASLAN004 1b mITT 600mg
¦U¶g¥§¡EASI¤U°´T«×«e8¶g¬Ûªñ¡C¡]¥Nªí¦³¬Û·í¦P®Éªý¾×IL4//IL13¸ê°Tªº®Ä²v)
www.nejm.org/doi/full/10.1056/nejmoa1610020 Dupilumab ¹Ï¤G¡C
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c p¡A21
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/11/11 ¤U¤È 06:24:28
²Ä 5763 ½g¦^À³
|
§Ú»{¬° ©Û¶Ò¯f¤Hªº²{ªp¶i«×
¤Î¬O§_¤w©Û¶Ò§¹¦¨
¨´¤µ¬ÒµL®ø®§
2b¥¿±´Á¤¤¼Æ¾Ú¤£´±«ü±æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/11/11 ¤U¤È 02:35:58
²Ä 5762 ½g¦^À³
|
§Ö¨ÓÓ¥¿¦Vªº´Á¤¤¼Æ¾Ú¡A¶^¯}¤j®aªº²´Ãè¡AÅý¾÷ºcªk¤H¨Ó¤£¤Î¤ÏÀ³ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/10 ¤W¤È 08:39:57
²Ä 5761 ½g¦^À³
|
²¤¶¡X§¨Ó¤½¥q¦V FDA ´£¥æ BLA ¥Î©óªvÀø¯SÀ³©Ê¥Öª¢ÃĪ« 02-11-2022 ¥´¦L
§ó¦hÃö©ó³oÓ¬G¨Æ EMA ±µ¨ü Almirall ªº lebrikizumab ¶ñ¥Rª«ªvÀø¯SÀ³©Ê¥Öª¢ 28-10-2022
¬ü°ê»sÃÄ¥¨ÀY§¨Ó (Eli Lilly) ¤w¦V¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½ (FDA) ´£¥æ¤F lebrikizumab ªº¥Íª«»s«~³\¥i¥Ó½Ð (BLA)¡Alebrikizumab ¬O¤@ºØ¥Î©óªvÀø¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ (AD) ªº¬ã¨s©Ê¥Õ²ÓM¤¶¯À (IL)-13 §í»s¾¯.
AD ¬O¤@ºØ IL-13 ¥D¾É¯e¯f¡A¨ä¤¤ IL-13 ¾ÉP¥Ö½§«Ì»Ù¥\¯à»Ùê¡Bæ±Äo¡B¥Ö½§¼W«p©M·P¬V©ö·P©Ê¡C Lebrikizumab ¦®¦b¥H°ª¿Ë©M¤O¡BºC¸ÑÂ÷³t²v©M°ª®Ä¤Oµ²¦X IL-13¡A¥H§í¨î IL-13 ªº¥Íª«¾Ç®ÄÀ³¡C
¸Ó´£¥æ±o¨ì¤F ADvocate 1 ©M ADvocate 2 16 ©P©M 52 ¶gµ²ªG¥H¤Î ADhere 16 ¶gµ²ªGªº¤ä«ù¡A³o¨Çµ²ªG¬OÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¥¦æ²Õ¡B¥þ²y¡BIII ´Áµû¦ô lebrikizumab §@¬°³æ¤@Àøªk¨Ã»P¼Ð·ÇÅ@²z¥~¥Î¥Ö½èÃþ©T¾JÁp¦X¥Î©ó«C¤Ö¦~©M¦¨¤H¡]12 ·³©Î¥H¤W¡^ªºÀø®Ä©M¦w¥þ©Êªº¬ã¨s¡C
®Ú¾Ú GlobalData ªº¼Æ¾Ú¡A¯SÀ³©Ê¥Öª¢ (AD) ¥«³õªº»ùȹwp±N±q 2020 ¦~ªº 64 »õ¬ü¤¸¼Wªø¨ì 2030 ¦~ªº 7 Ó¥Dn¥«³õªº 168 »õ¬ü¤¸¡A½Æ¦X¦~¼Wªø²v (CAGR) ¬° 10.1%¡C
BRIEF¡XLilly submits BLA to FDA for atopic dermatitis med 02-11-2022 Print
MORE ON THIS STORY EMA accepts Almirall¡¦s filling for lebrikizumab in atopic dermatitis 28-10-2022
Lilly and Almirall¡¦s lebrikizumab impresses a year in to eczema trial 07-06-2022
Lebrikizumab has significant impact on atopic dermatitis severity 12-04-2022
OTHER STORIES OF INTEREST Under geopolitics and market rout, Chinese biotechs center on data quality and survival 09-11-2022
AI firm Insilico could pocket $1.2 billion in Sanofi tie-up 09-11-2022
Broader label to support greater US growth for Libtayo 09-11-2022
RELATED COMPANIES Eli LillyArteaus TherapeuticsLilly RELATED DRUGS lebrikizumab US pharma major Eli Lilly has submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lebrikizumab, an investigational interleukin (IL)-13 inhibitor for the treatment of moderate-to-severe atopic dermatitis (AD).
AD is an IL-13 dominant disease in which IL-13 drives skin barrier dysfunction, itch, skin thickening and susceptibility to infection. Lebrikizumab is designed to bind IL-13 with high affinity, slow disassociation rate and high potency to inhibit the biological effects of IL-13.
The submission is supported by the ADvocate 1 and ADvocate 2 16-week and 52-week results, as well as the ADhere 16-week results, which are randomized, double-blind, placebo-controlled, parallel-group, global, Phase III studies that evaluated the efficacy and safety of lebrikizumab as a monotherapy and in combination with standard-of-care topical corticosteroids in adolescents and adults (12 years of age or older).
The atopic dermatitis (AD) market is expected to grow from a value of $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets at a compound annual growth rate (CAGR) of 10.1%, according to GlobalData. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/11/9 ¤U¤È 07:01:11
²Ä 5760 ½g¦^À³
|
´¼Àº¤@½u¯Ø¸¢ÀùÁ{§É¼Æ¾Ú¹F¼Ð ©ú¦~ªì¥Ó½Ð¬üÃÄÃÒ
¹d¦ëºô¥x¥_2022/11/09
´¼Àº (4162-TW) ¤µ (19) ¤é¤½§i¡AºX¤U¯Ø¸¢Àù·sÃĦw¯à±o (ONIVYDE) ªº²Õ¦XÀøªk¡AªvÀø¤@½u¯Ø¸¢Àùªº¥þ²y¼Ï¯Ã©ÊÁ{§É¸ÕÅç¡A¥Dn»P¦¸nµû¦ô«ü¼Ð§¡¹F¨ìÅãµÛÁ{§É·N¸q¡A«áÄò±N¶i¤@¨B¾ã²z¼Æ¾Ú¡A³Ì§Ö©ú¦~ªì¦V¬ü°ê FDA ´£¥XÃÄÃҥӽСC
´¼Àºªí¥Ü¡A¸ÓÁ{§É¸ÕÅç¬O¥Ñ±ÂÅv¦X§@¥ë¦ñ IPSEN ¨Ó°õ¦æ¡A±N¦w¯à±o·f°t¤ÆÀøÃÄ«~ Oxaliplatin (OX)¡B¸~½F¥ÎÃÄ 5 Fluorouracil (5-FU)¡B¸Ñ¬r¾¯ Leucovorin(LV) ªº²Õ¦XÀøªk¡A¨Ã¥H¥Ø«e¤@½u¯Ø¸¢Àù¼Ð·Ç²Õ¦XÀøªk§@¬°¸ÕÅç¹ï·Ó²Õ¡A¦¬®×¹ï¶H¬°Âಾ©Ê¯Ø¸¢¾ÉºÞ¸¢Àù±wªÌ¡A¦@ 770 ¤H¡C
®Ú¾Ú¸ÕÅçµ²ªGÅã¥Ü¡A¥Dnµû¦ô«ü¼ÐªºÁ`¦s¬¡´Á (OS)¡A¦w¯à±o²Õ¦XÀøªkÅãµÛÀu©ó¼Ð·Ç²Õ¦XÀøªk¡B¦¸nµû¦ô«ü¼Ð¤¤ªºµL´c¤Æ¦s¬¡®É¶¡¤]¦³ÅãµÛªº§ïµ½¡F¦w¥þ©Ê¤è±»P¹L¥hÁ{§É¤@ / ¤G´Á¼Æ¾Ú¹p¦P¡C
´¼Àºªí¥Ü¡A¦X§@¹Ù¦ñ IPSEN ±N·|§â¦¹¦¸¸ÕÅçµ²ªG¡A·f°t¹L¥h¤wÀò±oªº§Ö³t¼f¬d¸ê®æ¡A¦V¬ü°ê FDA »¼¥æ¾AÀ³¯g©µ¦ùªº¥Ó½Ð¡A³Ì§Ö©ú¦~ªì§¹¦¨¡A¥¼¨Ó¦A³°Äò¦V¼Ú¬w¡B¤é¥»¡B¥xÆWµ¥¦a°Ï´£¥X¤å¥ó¡A«Ý¨ú±oÃÄÃÒ«á±N·|Àò±o¨½µ{¸Oª÷¡C
¾Ú²Îp¡A¥þ²y¨C¦~¶EÂ_¥X 50 ¸U¦W¯Ø¸¢¾ÉºÞ¸¢Àù±wªÌ¡A¬ü°ê¨C¦~«h¦³ 6 ¸U¤H¡A¥Ñ©ó¦´Á¶¥¬q¨S¦³¯S©w¯gª¬¡A³q±`¯e¯fÂX´²¨ì¨Åé¨ä¥L³¡¦ì«á¤~·|³Qµo²{¡A¥Ø«e¦³¶EÂ_¥Xªº±wªÌ¤¤¡A¤£¨ì 2 ¦¨ªº¤H¦s¬¡´Á¶W¹L¤@¦~¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/11/9 ¤U¤È 12:29:25
²Ä 5759 ½g¦^À³
|
§Ú¤]ı±o¶}ÂåÀø«O°··|ij, ¬°¤°»òn±aCBO¥h???ì¨Ó¬O...... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/9 ¤W¤È 10:35:26
²Ä 5758 ½g¦^À³
|
Mr Stephen Doyle, CBO
CBO¶}©l¦£±ÂÅv¡B¨ÖÁʤF!¡B
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/8 ¤U¤È 10:18:13
²Ä 5757 ½g¦^À³
|
ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference ASLAN PHARMACEUTICALS LIMITED Tue, November 8, 2022 at 8:00 PM¡P1 min read ASLAN PHARMACEUTICALS LIMITED ASLAN PHARMACEUTICALS LIMITED SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London.
Please contact your Jefferies representative to request a one-on-one meeting with management. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/5 ¤U¤È 09:43:38
²Ä 5756 ½g¦^À³
|
2022¦~Q3°]³ø¥XÄl
investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2022-financial-and-operating
¤µ¦~«e¤T©uÀ禬¤w¶W¹L2021¥þ¦~¡A¤µ¦~¾P°â¦ôªñ87»õ¬ü¤¸¡C©ú¦~¦ô110»õ¬ü¤¸¡C
Dupixent /Dupilumab ³æ¦ì:¦Ê¸U¬ü¤¸ USA(¬ü°ê)// ROW (¨ä¥L°Ï°ì)//¤pp
2022 Q1 1,325.6//484.8//1,810.4 Q2 1,582.1//509.7//2,091,8 Q3 1,824.0//506.1//2,330.1 Q4 ¦Xp4731//1500//623
2021 Q1 961.5 //301.4//1262.9 Q2 1140//352//1492 Q3 1256.7//406.2//1662.9 Q4 1348//426//1774 ¦Xp 4712.8//1486//6198.8
2020 Q1 679.0 174.2 853.2 Q2 770.4 176.6 947.0 Q3 851.2 221.4 1072.6 Q4 925.6 246.4 1172.0 ¤pp3226.2 818.6 4044.8
2019 Q1 303.0 70.7 373.7 Q2 454.7 102.6 557.3 Q3 508.3 124.8 633.1 Q4 605.2 146.3 751.5 ¤pp 1,871.2 444.4 2,315.6
2018 Q1 117.2 14.2 131.4 Q2 180.9 28.3 209.2 Q3 219.6 43.0 262.6 Q4 258.6 60.2 318.8 ¤pp 776.3 145.7 922.0
2017 Q1 ******* Q2 ******* Q3 88.5 0.5 89.0 Q4 136.9 2.0 138.9 ¤pp 225.4 2.5 227.9 2017/03/28 FDA®Öã¤W¥« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤U¤È 03:45:42
²Ä 5755 ½g¦^À³
|
MOA
www.taiwan-pharma.org.tw/weekly/2166/2166-5-3.htm
Janus Kinases¡]JAKs¡^ÄݲÓM¤º»Ã¯À¡A¨Ã±N²ÓM½¤¤Wªº°T®§¶Ç¥X¡A¦b¶Ç»¼¸ô®|¤¤¡AJAKs·|«P¨Ï°T®§¶Ç¾É»PÂà¿ý¬¡¤Æ¦]¤l(STATs)ÁC»Ä¤Æ¤Î¬¡¤Æ¡A½Õ¸`²ÓM¤ºªº¾÷¯à¡A¥]¬A°ò¦]ªí²{¡A¼vÅT³y¦å²ÓM¹BÂà»P§K¬Ì²ÓM¥\¯à¡CJAK§í¨î¾¯¬°¼Ð¹v¦X¦¨§Ü·Àã¯fÃĪ«¡]targeted synthetic DMARDs, tsDMARDs¡^¬Oªñ¦~¨Ó·sµo®iªºÃĪ«Ãþ§O¡A¸g¥ÑJAKs½Õ¸`²ÓM°T®§¶Ç»¼¸ô®|¡Aªý¤îSTATsÁC»Ä¤Æ»P¬¡¤Æ¡A¶i¦Ó§í¨îµoª¢¤ÏÀ³¡A¬°²{¦³ÃĪ«µLªk¹F¨ìªvÀø¥Ø¼Ðªº¯f¤HªvÀø±a¨Ó·s¿ï¾Ü¡C¬Û¸û©ó¥Íª«»s¾¯¬ÒÄÝ°w¾¯¡A¦¹ÃþÃÄ«~ªº¯S¦â¬°¤fªA§ë¤©¡A¯f¤H¨Ï¥Î§ó«K§Q¡C«ØijªvÀø®É¾÷»PboDMARDs¬Û¦ü¡A¥Î©ócsDMARDs¦X¨ÖªvÀø«á¤´¤£¨£§ïµ½®É¡A¦ý¥Ø«e«ü¤Þ¤´Àu¥ý«Øij¨Ï¥ÎboDMARDs¡A¥¼¹FªvÀø¥Ø¼Ð¤~¦Ò¼{¨Ï¥ÎtsDMARDs¡C¥Ø«eªvÀø«ü¤Þ¤¤¦¬¿ýªº¬°JAK§í¨î¾¯tofacitinib¡Bbaricitinib¬Ò«D¿ï¾Ü©Ê§í¨îJAK-1¡A¨ä¤¤¦P®É§í¨îJAK-2¡B3·|¾ÉP³y¦å·F²ÓM¡]hematopoietic cell)¡B¬õ¦å²y¥Í¦¨¯À¡]erythropoietin¡^µ¥«n¥Í²z¾÷Â઺°T®§¶Ç»¼³QªýÂ_¡A¶i¤@¨B³y¦¨¬ÛÃö°Æ§@¥Î¡C
¿ï¾Ü©ÊJAK-1§í¨î¾¯³z¹L±M¤@©Ê§í¨î¡A´Á±æ¯à´î§C¦]§í¨îJAK-2¡B3©Ò±a¨Óªº°Æ§@¥Î¡A¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^©ó2019¦~8¤ë16¤é¨Ì¾ÚFleischmann µ¥¤Hµoªíªº¸ÕÅçµ²ªG¡A®Öã¿ï¾Ü©ÊJAK-1§í¨î¾¯ upadacitinib¡]UPA¡^¥Î©óªvÀø¤¤««×¦¨¦~RA¯f¤H¡C¦¹ÀH¾÷¸ó°ê²Ä¤T´Á¦w¼¢¾¯¹ï·Ó¸ÕÅ笰´Á26¶g¡A¦@¦¬¯Ç449¦ì¨ü¸ÕªÌ¡A¬Ò±w¦³¬¡°Ê©ÊRA¥B¨Ï¥ÎMTXéwªvÀø¦Ü¤Ö¤TÓ¤ë¥H¤W¡A¥¼´¿¨Ï¥Î¹L¨ä¥LboDMARDs©ÎtsDMRADs¶W¹L¤TÓ¤ë¡A¥B¦bªvÀø«á¤´ºû«ù¯e¯f¬¡©Ê¡C¨ü¸ÕªÌ¸gÀH¾÷¤À¬£¬°¤T²Õ¡G¨C¤é¤fªAUPA 15 mg¡B¨C¨â¶g¥Ö¤Uª`®gadalimumab¡]ADA¡^40 mg¥H¤Î¦w¼¢¾¯²Õ¡A¦U²Õ¬ÒÄ~Äò¨Ï¥Îì³B¤è¤§Ã©w¾¯¶qMTX¡C¸ÕÅçµ²ªGÅã¥Ü¡A¦b²Ä 12 ¶gªºµû¦ô¡A»P¦w¼¢¾¯²Õ¤ñ¸û¡A¹F¨ì¸~µÈ¤ÎIJµhÃö¸`¼Æ§ïµ½¹FACR20¡]American College of Rheumatology 20% improvement criteria¡^ªº¯f¤H¤ñ²v¡A±µ¨üUPA 15 mg»P¦w¼¢¾¯²Õ¤À§O¬°71% »P 36%¡]p¡Ø0.001)¡A¥B¦b26¶g¤´ºû«ù¸û¦w¼¢¾¯²Õ¨Îªºªí²{¡F»P ADA ²Õ¤ñ¸û¡A¦b²Ä26¶g¹F¨ì¸~µÈ¤ÎIJµhÃö¸`¼Æ§ïµ½¹F50%¡]ACR50¡^ªº¯f¤H¤ñ²v¡A±µ¨üUPA 15 mg»P ADA ²Õ¤À§O¬°54% »P 42%¡]p¡Ø0.001)¡A¬Ò¹F²Îp¤WÅãµÛ®t²§¡C¦w¥þ©Ê¤è±¡A©ó²Ä26¶g²Îp¥ô¦ó¤£¨}¨Æ¥ó¡]AE¡^ªºµo¥Í¤ñ¨Ò¡A¦b UPA 15 ²@§J¡B¨C¨â¶g¥Ö¤Uª`®gADA 40 mg»P¦w¼¢¾¯²Õ¤À§O¬°64.2%¡B60.2% »P 53.2%¡A«e¨â²Õµo¥Íªº¤ñ¨Ò¬Û·í¡CUPA©ó¸ÕÅ礤¥X²{ªº¤£¨}¤ÏÀ³¥H·P¬V¡]¦p¡G±aª¬疱¯l)¡B¦Ù»Ä¿E»Ã¯À¡]creatine phosphokinase, CPK¡^¤W¤É¡BÀR¯ß¦å®ê®ê¶ë¡]venous thromboembolic event, VTE¡^¬°¥D¡C¦Ó¥t¤@Ó¿ï¾Ü©ÊJAK-1§í¨î¾¯ filgotinib ¤]¦b²Ä¤T´ÁÁ{§É¸ÕÅ礤¬°Ãøªv«¬ªº¤¤««×¦¨¦~RA¯f¤H±a¨ÓÅãµÛªºÁ{§É§ïµ½¡A¨Ã©ó2019¦~12¤ë16¤é´£¥X·sÃĥӽСC |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤U¤È 02:25:46
²Ä 5754 ½g¦^À³
|
Upadacitinib¤T´Á¡]¤fªAÃĪ«¡^JAK§í¨î¾¯ MOA
IL4+IL4Ra+IL13Ra1 ²£¥Í«¬II½Æ¦X¨üÅé¡A¦A¨Ó´N²£¥ÍJAK1/2,IgE¤U´åªº¤ÏÀ³¤À¤l¡C
IL13+IL13Ra1+IL4Ra²£¥Í«¬II½Æ¦X¨üÅé¡A¦A¨Ó´N²£¥ÍJAK1/2,IgE¤U´åªº¤ÏÀ³¤À¤l¡C
¥H¤W2Ó³~®|¤À§O¥Ñ¤W´åªºIL4¡BIL13¶}©l¡C
§í¨îJAK²£¥Í¸û¨ÎÀø®Ä¡A¥u¯à¤Ï±ÀDupilumab «Ê¦íIL4Ra ªº°T®§¶Ç»¼¤´¦³º|¬}¡C
¦ÓASLAN004Àø®Ä¥i±µªñ¤fªAÃĪ«¡A«ÊÂêIL4¤ÎIL13°T®§¶Ç»¼§ó±j¡C
¤@¤@¦ô¦y®p¾P°â35»õ¬ü¤¸¡]¦P½÷·çªº¤fªAÃĪ«¡^
IGA0,1
15mg 48.1% vs 8.4%¡]®t²§40%¡^ 30mg 62% vs 8.4%¡]®t²§54%¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤U¤È 01:49:22
²Ä 5753 ½g¦^À³
|
¨ä¹ê¨C¶g¤@°w8¶g´N¥i¼ÒÀÀ¥X
IGA0,1 mITT 7/16=44% (7+6)/(16+6-1)=61% ì¦]¦P¤U¡D
EASI75=81%
¦A¥[9-16¶g¡B¨C¶g¤@°w¡B¥DnªvÀø°ò½uEASI>41 ªº±Ú¸s¡D
«D¶Ç统AD±wªÌ¥²¶·³Q±Æ°£¡D
............ 004-1b mITT*8¶g¼ÒÀÀ
EASI75 11/16=69%... mITT (11+6)/(16+6-1)=81% ¥t¥[6Ó°ò½u=EASI19»´¯gªÌ¡B¦ý°ªTRAc/°ªIgE
«h6/6Àø®Äªñ100%
¥t¥~3¤H¤¤Â_¡B°²³]´î¤Ö¬°2¤H¡B
¥Ø¼ÐEASI75=81% IGA0,1=65%(Lebrikizumab EASI75-16%=IGA0,1ªºÀø®Ä¡D)
......16 ¶gªvÀø
¯uªº¦³¾÷·|¡B¦p¤½¥q©Ò¨¥³ô¤ñ¤fªAÃÄ®Ä |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤W¤È 10:46:32
²Ä 5752 ½g¦^À³
|
¦UÃĦy®p¾P°â¤@2==004 ¼ÒÀÀ¤G
1¡ALebrikizumab ¨âÓAD¤T´ÁÁ{§ÉÀø®Ä¥Dn«ü¼ÐIGA0,1 ¦©°£¹ï·Ó²Õ¡]16¶g¡^¡ã¦ô¦y®p¾P°â45»õ¬ü¤¸(¬ü°ê¤ÀªR®vªñ´Á¤ÀªR) AD¤@l 30%¡]43%-13%¡^//52¶g©Ô°ª¨ì¹êÅç²Õ46% AD¤@2 22% (33%-11%)//52¶g©Ô¨ì¹êÅç²Õ39%
2¡ADupilumab ¨âÓAD3´Á¡ã¦©°£¹ï·Ó²Õ¡A¦ôAD¦y®p¾P°â80»õ¬ü¤¸(¤½¥q¥»¨¦ôl40»õ¦yûß¾P°âx55%=80»õ¬ü¤¸¬°AD.) Solo1 28%(38%-10%)//52¶g°¨ì¹êÅç²Õ¬ù36% Solo2 28%(36%-8%)//52¶g°¨ì¹êÅç²Õ¬ù34%
3¡AASLAN004 2b Á{§É16¶gx¨C¶g¤@°w80%Àu©óDupilumab¡]¦©°£¹ï·Ó²Õ¡^ 28%x180=52%¡K73»õ¬ü¤¸¾P°â
ASLAN004 2b 16¶gx¨C¶g¤@°w¡AÀø®Ä³ô¤ñ¤fªAÃĤG½u ´Á±æÈ64%¡ã15%=49%¡]¤é«á¤T´Á¹ï·Ó²Õ·|°¨ì8¡ã10%¡A¹êÅç²Õ¤@¹ï·Ó²Õ®t²§©Ô°ª¨ì52%¥ª¥k¡^
¦Xp¦ôASLAN004 ¦y®p¾P°â 73¤Q17¡×90»õ¬ü¤¸ ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ 4¡AUpadacitinib¤T´Á¡]¤fªAÃĪ«¡^¤@¤@¦ô¦y®p¾P°â35»õ¬ü¤¸¡]¦P½÷·çªº¤fªAÃĪ«¡^
IGA0,1
15mg 48.1% vs 8.4%¡]®t²§40%¡^ 30mg 62% vs 8.4%¡]®t²§54%¡^
........ 004¥[¤W¨ä¥L¾AÀ³¯gµ´¹ï°_¹L100»õ¬ü¤¸¦yºÝ¾P°â
©Ò¥H©ú¦~©³ªº¤G½u¸Ñª¼¤ñQ2ªº¸Ñª¼¨Óªº§ó«n¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤W¤È 09:26:14
²Ä 5751 ½g¦^À³
|
³¯¤j¡B 2018/2019¨âÓ¤å¥óªº«O±K©µªø¨ì2027¦~.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/11/4 ¤W¤È 09:03:02
²Ä 5750 ½g¦^À³
|
¤Ñ©R¤j
¤U¦C2«Ê«H¡A¦³¤°»ò¯S®í·N¸q¶Ü
¬ü°ê ÃÒ¨é¥æ©ö©eû·| 2022 ¦~ 11 ¤ë 3 ¤é ±Â¤©¾÷±KªvÀøªº©R¥O ®Ú¾Ú 1934 ¦~ÃÒ¨é¥æ©öªk ªü´µÄõ»sÃĦ³¤½¥q ¤å¥ó¸¹ 1-38475 - CF#37122 _____________________ ASLAN Pharmaceuticals Limited ®Ú¾Ú³W«h 24b-2 ´£¥æ¥Ó½Ð ½Ð¨D©µªø¥ý«e±Â¤©ªº¹ï¨ä«H®§ªº«O±K³B²z ±Æ°£¦b 2019 ¦~ 1 ¤ë 9 ¤é´£¥æªº 6-K ªí®æªºªþ¥ó¤§¥~¡C ®Ú¾Ú ASLAN Pharmaceuticals Limited ªº³¯z¡A¥» «H®§²Å¦X«O±K°Ó·~©Î°]°È«H®§ªº±ø¥ó «H®§¦Û¥Ñªk¡A5 U.S.C. 552(b)(4)¡A¤½¥q°]°È³¡¦³ ¨M©w¤£¤½¶}¡C ¦]¦¹¡A±q ¥H¤U®i«~¦b«ü©wªº®É¶¡¬q¤º¤£·|¦V¤½²³µo¥¬¡G ¹Ïªí 10.1 ¦Ü 2027 ¦~ 12 ¤ë 20 ¤é ¹ï©ó©eû·|¡A¥Ñ¤½¥q°]°È³¡®Ú¾Ú ±ÂÅv
¬ü°ê ÃÒ¨é¥æ©ö©eû·| 2022 ¦~ 11 ¤ë 3 ¤é ±Â¤©¾÷±KªvÀøªº©R¥O ®Ú¾Ú 1933 ¦~ÃÒ¨éªk ªü´µÄõ»sÃĦ³¤½¥q ¤å¥ó¸¹ 333-223920 - CF#35819 _____________________ ASLAN Pharmaceuticals Limited ®Ú¾Ú³W«h 406 ´£¥æ¥Ó½Ð ½Ð¨D©µªø¥ý«e±Â¤©ªº¹ï¨ä«H®§ªº«O±K³B²z ±q 2018 ¦~ 3 ¤ë 26 ¤é´£¥æªº F-1 ªí®æµn°OÁn©úªºªþ¥ó¤¤±Æ°£¡A ¸g×¥¿¡C ®Ú¾Ú ASLAN Pharmaceuticals Limited ªº³¯z¡A¥» «H®§²Å¦X«O±K°Ó·~©Î°]°È«H®§ªº±ø¥ó «H®§¦Û¥Ñªk¡A5 U.S.C. 552(b)(4)¡A¤½¥q°]°È³¡¦³ ¨M©w¤£¤½¶}¡C¦]¦¹¡A±q ¥H¤U®i«~¦b«ü©wªº®É¶¡¬q¤º¤£·|¦V¤½²³µo¥¬¡G ¹Ïªí 10.5 ¦Ü 2027 ¦~ 12 ¤ë 20 ¤é ¹Ïªí 10.6 ¦Ü 2027 ¦~ 12 ¤ë 20 ¤é ¹Ïªí 10.7 ¦Ü 2027 ¦~ 12 ¤ë 20 ¤é ¹ï©ó©eû·|¡A¥Ñ¤½¥q°]°È³¡®Ú¾Ú ±ÂÅv¡G ¹F®R«¢¯ý ª¾ÃѺ޲z¿ì¤½«Ç¥D¥ô |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤W¤È 08:54:09
²Ä 5749 ½g¦^À³
|
°²³]¤G½uÀø®Ä¹F¼Ð ¥¼¨Ó¤T´Á¤@½u¥²·|¥[¤J¨C¶g¤@°w¡D Y¦p预´Á80%Àu©óDupilumab «h¤@½uÃĪº¦yºÝ¾P°â73»õ¬ü¤¸´N«Ü¦X²z.
预´ÁASLAN004ªº3´ÁÁ{§É¨C¶g¤@°wÀø®Ä °ò½uEASI31//IGA3=51% EASI75=78% vs 15%(®t²§63%) IGA0.1=62% vs 10%(®t²§52%)
©Ò¥H¤½¥q°õ¦æ¤G½uÁ{§É¬O¹ïªº¡D
¤@½u16¶gx¨C¶g¤@°w75¤H¥i¥H¤£¥Î°µ¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤W¤È 05:27:11
²Ä 5748 ½g¦^À³
|
¦b³\¦h¾AÀ³¯g¤W
¦b®a¥´SC(¥Ö¤Uª`®g)
¨C¶g¤@°w¥ý±À¥X¡B¦A±À¨C¤G¶g¤@°w(Àø®Ä¬Û¦P)
±wªÌ¤j³£ÁÙ¬O°¾¦n¨C¶g¤@°w¡D ¨C¶g¤@°w¦n°O¡B¦P¼Ë»ù®æ¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤W¤È 04:59:09
²Ä 5747 ½g¦^À³
|
¨Ì004-1b mITT*8¶g¼ÒÀÀ
EASI75 11/16=69%... mITT (11+6)/(16+6-1)=81% ¥t¥[6Ó°ò½u=EASI19»´¯gªÌ¡B¦ý°ªTRAc/°ªIgE
«h6/6Àø®Äªñ100%
¥t¥~3¤H¤¤Â_¡B°²³]´î¤Ö¬°2¤H¡B
¥Ø¼ÐEASI75=81% IGA0,1=65%(Lebrikizumab EASI75-16%=IGA0,1ªºÀø®Ä¡D)
......16 ¶gªvÀø
¯uªº¦³¾÷·|¡B¦p¤½¥q©Ò¨¥³ô¤ñ¤fªAÃĮġD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤W¤È 04:37:01
²Ä 5746 ½g¦^À³
|
½Ð¦U¦ì¤j¤j
¼g«Hµ¹ ASLN ¤½¥q
n¨D¼W¤@Ó75¤Hªº¤@½ux¨C¶g¤@°wªºAD Á{§É¡D
ÅçÃÒÀø®Ä³ô¤ñ¤fªAÃĪ« IGA0,1=64%-15%=49% EASI75=80-24%=56%
AD ¦y®p¾P°â¤W¬Ý70»õ¬ü¤¸
¥[¨ä¥L¾AÀ³¯g>100»õ¬ü¤¸¤¸
Àø®Ä¤j©ó¤@¤Á!
(¦b¦w¥þ¦Pµ¥ªºª¬ªp¤U)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤W¤È 04:16:49
²Ä 5745 ½g¦^À³
|
×¥¿¤@l Dupilumab ¹s°â»ù3300¬ü¤¸/600mg¡B¤½¥q¥X¼t»ùx80%=2660¬ü¤¸/600mgªºÀ禬 »s³y¦¨¥»=2660*10%=266/600mg 0.45 ¬ü¤¸/mg
°²³]ASLAN004 16¶gx¨C¶g¤@°w·í¤@½uÃÄ Àø®Ä³ô¤ñ¤fªAÃÄ IGA0,1=62%-10%(¹ï·Ó组)=52% vs Dupilumab ªºÀø®Ä38%-10%=28%
52%/28%=186%
°²³]¨C¤ëq»ù¬Û¦P3300¬ü¤¸/4°w
ASLAN004¤@ ½uÃĪ«¥i¾P80»õ¬ü¤¸¥i´Á
¦¨¥»400mg*4=1600mg...ASLAN004 ¤ñDupilumab 600mg¦h1000 mg
¦¨¥»¦h¥X1000*0.45=450¬ü¤¸/¨C¤ë 16 ¶g¦¨¥»¤ñDupilumab¦h¥X1800¬ü¤¸
1800/24000(¦~¥§¡ÃĶO)=7.5%(17-52¶g¥i«ì´_¥Î¤G¶g¤@°w/¥|¶g¤@°w¡D
80»õx(60%-7.5%)=52»õ¬ü¤¸²b§Q ©Î¬Û·í80*92.5%=73»õ¬ü¤¸ªºDupilumab 销°â(60%²b§Q)
µ²½×¡G«Øij ASLN004 ¨C¶g¤@°wx16¶gªº¤@½uÃĪ«¥i¨Ï¦y®p销°â¥Ñ26»õªº¤G¶g¤@°w¡B´£¤É¨ì73»õ¬ü¤¸
¤G½uÃıN«D±`¤Ö¡D(¦]ASLAN004. ¬O¤@½u¥D¤O)
¬GASLN ¤½¥qÀ³±N75¤Hªº¤GÃĪ«¼È½w¡B §ï¬°¤@½u75¤H¡B¨ú±o³ô¤ñ¤fªAÃĪ«ªvÀøªºÀø®Äµ²ªG¡D
¤T´Á¼W¥[¨C¶g¤@°wªºÁ{§É(¦Pdupilumab) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤W¤È 04:03:22
²Ä 5744 ½g¦^À³
|
Dupilumab ¹s°â»ù3300¬ü¤¸/600mg¡B¤½¥q¥X¼t»ùx80%=2660¬ü¤¸/600mgªºÀ禬 »s³y¦¨¥»=2660*10%=266/600mg 0.45 ¬ü¤¸/mg
°²³]ASLAN004 16¶gx¨C¶g¤@°w·í¤@½uÃÄ Àø®Ä³ô¤ñ¤fªAÃÄ IGA0,1=62%-10%(¹ï·Ó组)=52% vs Dupilumab ªºÀø®Ä38%-10%=28%
52%/28%=186%
°²³]¨C¤ëq»ù¬Û¦P3300¬ü¤¸/4°w
ASLAN004¤@ ½uÃĪ«¥i¾P80»õ¬ü¤¸¥i´Á
¦¨¥»400mg*4=1600mg...ASLAN004 ¤ñDupilumab 600mg¦h1000 mg
¦¨¥»¦h¥X1000*0.45=450¬ü¤¸/¨C¤ë 16 ¶g¦¨¥»¤ñDupilumab¦h¥X1800¬ü¤¸
1800/24000(¦~¥§¡ÃĶO)=7.5%
80»õx(40%-7.5%)=26»õ¬ü¤¸²b§Q ©Î¬Û·í80*92.5%=73»õ¬ü¤¸ªºDupilumab 销°â(40%²b§Q)
µ²½×¡G«Øij ASLN004 ¨C¶g¤@°wx16¶gªº¤@½uÃĪ«¥i¨Ï¦y®p销°â¥Ñ26»õªº¤G¶g¤@°w¡B´£¤É¨ì73»õ¬ü¤¸
¤G½uÃıN«D±`¤Ö¡D
¬GASLN ¤½¥qÀ³±N75¤Hªº¤GÃĪ«¼È½w¡B §ï¬°¤@½u75¤H¡B¨ú±o³ô¤ñ¤fªAÃĪ«ªvÀøªºÀø®Äµ²ªG¡D
¤T´Á¼W¥[¨C¶g¤@°wªºÁ{§É(¦Pdupilumab)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/3 ¤U¤È 09:09:27
²Ä 5743 ½g¦^À³
|
¦UÃĦy®p¾P°â
1¡ALebrikizumab ¨âÓAD¤T´ÁÁ{§ÉÀø®Ä¥Dn«ü¼ÐIGA0,1 ¦©°£¹ï·Ó²Õ¡]16¶g¡^¡ã¦ô¦y®p¾P°â45»õ¬ü¤¸ AD¤@l 30%¡]43%-13%¡^//52¶g©Ô°ª¨ì¹êÅç²Õ46% AD¤@2 22% (33%-11%)//52¶g©Ô¨ì¹êÅç²Õ39%
2¡ADupilumab ¨âÓAD3´Á¡ã¦©°£¹ï·Ó²Õ¡A¦ôAD¦y®p¾P°â80»õ¬ü¤¸ Solo1 28%(38%-10%)//52¶g°¨ì¹êÅç²Õ¬ù36% Solo2 28%(36%-8%)//52¶g°¨ì¹êÅç²Õ¬ù34%
3¡AASLAN004 2b Á{§É16¶g¤G¶g¤@°w¤½¥q¦ô8%Àu©óDupilumab¡]¦©°£¹ï·Ó²Õ¡^ 28%x108%=30.3%
ASLAN004 2b 16¶gx¨C¶g¤@°w¡AÀø®Ä³ô¤ñ¤fªAÃĤG½u ´Á±æÈ64%¡ã15%=49%¡]¤é«á¤T´Á¹ï·Ó²Õ·|°¨ì8¡ã10%¡A¹êÅç²Õ¤@¹ï·Ó²Õ®t²§©Ô°ª¨ì52%¥ª¥k¡^
¦Xp¦ôASLAN004 ¦y®p¾P°â 26¤Q17¡×43»õ¬ü¤¸ ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ 4¡AUpadacitinib¤T´Á¡]¤fªAÃĪ«¡^¤@¤@¦ô¦y®p¾P°â35»õ¬ü¤¸¡]¦P½÷·çªº¤fªAÃĪ«¡^
IGA0,1
15mg 48.1% vs 8.4%¡]®t²§40%¡^ 30mg 62% vs 8.4%¡]®t²§54%¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/11/3 ¤U¤È 05:40:43
²Ä 5742 ½g¦^À³
|
to©t¨à¤j §Ú¤]¬O´Á«Ý©_ÂÝ°Ú ¥u¬O¥Ø«e´N¬O°µ¦n³ÌÃa¥´ºâ¡A¥áµÛ¤£ºÞ ³o¼Ë¤£·|¼vÅT¦Û¤v¤ß±¡ ©Î³\þ¤Ñ¬ðµM¦¨¥\¤F´N¹³µo¤@µ§¾î°] ¤]¤£¿ù°Õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·RµL10148552 |
µoªí®É¶¡:2022/11/3 ¤W¤È 11:05:28
²Ä 5741 ½g¦^À³
|
ªÑ²¼¯u¬O¤@Ó¯«©_ªº°Ó«~! º¦®É¬Ý¦n! ¶^®É¬ÝÃa! 1¦~«e¡A6¤¸ªº®ÉÔ»¡·Ç³Æ¼Q¤F°Õ¡A¸Ñª¼¤@©w¦¨¥\¡C 1¦~«á¡A0.35¤¸ªº®ÉÔ»¡¤½¥q¤@©w´£¦¬Ý¨ì¼Æ¾Ú¡A¸Ñª¼¤j¾÷²v¥¢±Ñ¡C ¦ý¡A¸Ñª¼µ²ªG¨Ã¥¼¥X¨Ó¡A³Ót¥¼¤À¡C 6¤¸¨g¶R¡A0.35¨g½æ¡A¤£Åܪº¬O¤H©Ê-°l°ª±þ§C¡C«¢~~~~~~~~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/11/3 ¤W¤È 09:41:38
²Ä 5740 ½g¦^À³
|
¬Q±ß9ÂI51¤À¶R¶i70¸UªÑ¡AªÑ»ù0.365¤¸¬üª÷¡A¬ù26¸U¬üª÷¡A¥x¹ô830¸U â±á3ÂI40¤À¶R¶i148¸UªÑ¡AªÑ»ù0.3405¤¸¬üª÷¡A¬ù50¸U¬üª÷¡A¥x¹ô1600¸U ³o¨âµ§³£¬O³æµ§©w»ù©w®É¥æ©ö¡An¶Rªº¤Hn§ä¨ì½æ®a(n½æªº¤Hn§ä¨ì¶R®a)¡A¨ÃÁ¿¦n¥æ©ö®É¶¡©M»ù®æ¡A ²{¦b¬OªÑ»ùµ´¹ï§CÂI¡A©Ò¥H¤£À³¸Ó¬O¦³¤H·Q½æ¡C¦Ó¬O¦³¤H·Q¶R¡C(ÅÞ¿è) ¦ý¤]¦³¥i¯à¬O¥ª¤â½æµ¹¥k¤â¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/3 ¤W¤È 06:10:54
²Ä 5739 ½g¦^À³
|
¯È¤j, ¤½¥qªº¥«½Õ¦p¦¹°²³]Àø®Ä¤è®×¡B¥L̬O¦³¼Æ¾Ú¦b¤âªº±M®a¡B§Ú¥u¬O¼ÒÀÀ¸Õºâ¦Ó¤w¡B ¤]§Æ±æ¦³©_ÂÝ¡B¥´§¹²Ä¤T°w«á¦p¦P¥´§¹²Ä¤K°w¦³4-6¶g´Á¶¡¤£¥´°w¦Ó¥Íª««ü¼Ð¬Oéwªº¤£·|¤Ï¼u¡B³o¼Ë«á±ªº4¤@9°wªºÀø®Ä¯à©ñ¤j¨ì¤fªAÃĪ«ªºÀø®Ä¼ç¤O¡B¦¹®É¤~¯à¦b²Ä¤@½uÃĪ«¤¤¤j´T»â¥ýDupilumab, ¤è¯à¦³¦Ê»õ¡B¬ü¤¸ªº¾P°â¼ç¤O¡D
¤£¹L¬Ý¤FASLAN004±À¥X16¶gx¨C¶g¤@°wªºÁ{§É³]p´N±o¨Ì¤½¥q°²»¡¨Ó¼ÒÀÀ¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¯È¤W´I¶Q10134993 |
µoªí®É¶¡:2022/11/3 ¤W¤È 12:21:28
²Ä 5738 ½g¦^À³
|
A+B=26+17 =43»õ¬ü¤¸¤§³Ì°ª¾P°â 2023³Q¦~©³¨ÖÁÊ¥«È¦ô¬ù20-25»õ¬ü¤¸ ¨CªÑ20-25¬ü¤¸´Á±æÈ¡D ------------------------------ ¦L¶H¤¤À³¸Ó¬O¤Ñ©R¥S¦ô¹L³Ì§Cªº¤@¦¸
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/11/2 ¤U¤È 11:26:49
²Ä 5737 ½g¦^À³
|
¦³¤H§Û©³嘞
9ÂI51¤À¶R¶i70¸UªÑ¡AªÑ»ù0.37¤¸¬üª÷¡A¬ù26¸U¬üª÷¡A¥x¹ô830¸U
¬ù¶R¶i¨È·à±d ¦Ê¤À1ªÑ¥÷
¡Ä |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/11/2 ¤U¤È 02:42:46
²Ä 5736 ½g¦^À³
|
ì¥ý¹w´Á¦~©³À³¦³´Á¤¤¼Æ¾Ú¡A¥H²{¤µªºªÑ»ù¨Ó¬Ý¡A¥Ø«eªºª¼¼Æ¾Ú¥i¯àÁÙ¤W¤£¤FÂi±;¦Ñ·à¤Ín¦hÂI@¤ß¤F¡AÁöµM¦p¦P«Ó°¶¤j©Ò»¡±o¤@¼Ë¡A¦³Ãz±¼ªº¥´ºâ¡A¦ýÁÙ¬O´Á«Ý¦³©_ÂÝ¡A¦Ü©ó·s·à¤Í´N¦Û¦æ§PÂ_¤F¡A¦]³o»ò§C»ù¡A·ÀI¦Ût~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/2 ¤U¤È 02:20:29
²Ä 5735 ½g¦^À³
|
¤G缐75¤HADÁ{§É¸Ñª¼¤½¥q©ã¦b2023¦~¡A¥¿±`¦b¦~©³¡C
©Ò¥H295¤H¡AQ2¸Ñª¼³ø§i¡A¤£·|¦³¤G缐ªvÀø¸ê®Æ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/2 ¤U¤È 01:02:33
²Ä 5734 ½g¦^À³
|
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c
11¤ë¥÷¤½¥q³Ì·s²³ø¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/2 ¤W¤È 10:34:34
²Ä 5733 ½g¦^À³
|
Ó¤H¦ô ¤@¡B _________________________ ASLAN004 2B 16¶g´Á±æÈ (¨C¤G¶g¤@°w) 295¤H °ò½u¦ô(EASI26~28)
EASI75 69% VS 24% IGA0.1 46% VS 15%
ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3%
µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤@½uÃÄÀø®Ä(¨C¤G¶g¤@°w) ¥i8% °ªDupilumab °w¨b¾¯¾÷·|¤j.
¤G¡BASLAN004 2B 16¶g´Á±æÈ (¨C¶g¤@°w) 75¤H °ò½u¦ô(EASI26~28)
EASI75 73%~80% VS 24% IGA0.1 57%~64%% VS 15%
ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3%
µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤G½uÃÄÀø®Ä(¨C¶g¤@°w) ¥i¤ñ¤fªAUpadacitinib ¾÷·|¤j. .
¤T¡B¥«³õ¹w´Á
¤@½uÃĪ«47%¬Û¹ï©óDupilumab°¾¦n, ¥Ñ©ó¤G½uÃĪ«Àu²§ªí²{¡A¥¼¨Ó52¶gÀø®Ä¦³¼ç¤O¦A©Ô°ª¡B¥[¤W¨ä¥LÃĪ«¦Ò¶q¡B¥«¦û¦ô¬ùDupilumab1/3=80*1/3=26»õ¬ü¤¸¡KA
¤G½uÃĪ« 46% °¾¦n¬Û¹ï©ó¤fªAÃĪ«¡D ¨Ì¦~ªì½÷·ç¦Û¦ôAD ¤fªAÃÄ¥i¾P35»õ¬ü¤¸¡B ¦ô¬ù¦³ªñ½÷·ç1/2¥«¦û¬ù17»õ¬ü¤¸¥i´Á...B
A+B=26+17 =43»õ¬ü¤¸¤§³Ì°ª¾P°â 2023³Q¦~©³¨ÖÁÊ¥«È¦ô¬ù20-25»õ¬ü¤¸ ¨CªÑ20-25¬ü¤¸´Á±æÈ¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/2 ¤W¤È 08:54:08
²Ä 5732 ½g¦^À³
|
Upadacitinib AD ¤T´ÁÁ{§Éµ²ªG:
1. Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1)
°ò½u EASI29(15mg)//EASI30(30mg)//EASI28(¹ï·Ó²Õ)
°ò½u IGA=4 46%(15mg)//47%(30mg)//45%(¹ï·Ó²Õ)
clinicaltrials.gov/ct2/show/results/NCT03569293?term=NCT03569293&draw=2&rank=1
2.16¶g Àø®Ä
(1).EASI75 ¹êÅç²Õvs¹ï·Ó²Õ
15mg 69.6% vs 16.3% 30mg 79.7% vs 16.3%
(2).IGA0,1
15mg 48.1% vs 8.4% 30mg 62% vs 8.4%
_________________________ Ó¤H¦ô ASLAN004 2B 16¶g´Á±æÈ (¨C¶g¤@°w) 75¤H °ò½u¦ô(EASI26~28)
EASI75 73%~80% VS 24% IGA0.1 57%~64%% VS 15%
ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3%
µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤G½uÃÄÀø®Ä(¨C¶g¤@°w) ¥i¤ñ¤fªAUpadacitinib ¾÷·|¤j.
----------------------- 3.AD-2/AD-3 没¤½¶}Á{§Éµ²ªG¸ê®Æ
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) clinicaltrials.gov/ct2/show/NCT03607422?term=NCT03607422&draw=2&rank=1
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up) clinicaltrials.gov/ct2/show/NCT03568318?term=NCT03568318&draw=2&rank=1
---------------------------------------------------------------------------------------
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/1 ¤U¤È 05:59:47
²Ä 5731 ½g¦^À³
|
www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s004lbl.pdf RINVOQ® (upadacitinib) FDA ¼ÐÅÒÀÉ
ĵ§i¡GÄY«·P¬V¡B¦º¤`²v¡B
´c©Ê¸~½F¡A¥Dn¤£¨}¤ß¦åºÞ ¨Æ¥ó¡]MACE¡^©M¦å®ê§Î¦¨
¦³Ãö§¹¾ãªº¶Â®Øĵ§i¡A½Ð°Ñ¾\§¹¾ãªº³B¤è«H®§¡C • ÄY«²Óµß¡B¯uµß¡B¯f¬r©M·P¬Vªº·ÀI¼W¥[ ¾÷·|©Ê·P¬V¾ÉP¦í°|©Î¦º¤`¡A ¥]¬AªÍµ²®Ö¡]TB¡^¡C¨Ï¥Î RINVOQ ¶i¦æ¤¤Â_³B²z ¦pªGµo¥ÍÄY«·P¬V¡Aª½¨ì·P¬V±o¨ì±±¨î¡C´ú¸Õ ªvÀø«e©MªvÀø´Á¶¡ªº¼ç¥ñ©Êµ²®Ö¯f¡FªvÀø¼ç¥ñ©Êµ²®Ö¯f §Q¥Î¡C¦bªvÀø´Á¶¡ºÊ´ú©Ò¦³±wªÌªº¬¡°Ê©Êµ²®Ö¯f¡A¬Æ¦Ü ªì©l³±©Ê¡B¼ç¥ñ©Êµ²®Ö¯f¸ÕÅ窺±wªÌ¡C (5.1) • §ó°ªªº¥þ¦]¦º¤`²v¡A¥]¬AÖ`¦º ¥t¤@ºØ Janus ¿E酶 (JAK) §í»s¾¯¾ÉP¤ß¦åºÞ¦º¤` »PÃþ·Àã©ÊÃö¸`ª¢¤¤ªº¸~½FÃa¦º¦]¤l (TNF) ªýº¢¾¯¤ñ¸û (RA) ±wªÌ¡C (5.2) • ±µ¨ü RINVOQ ªvÀøªº±wªÌµo¥Í¤F´c©Ê¸~½F¡C ¥t¤@ºØ JAK ªº²O¤Ú½F©MªÍÀùµo¯f²v§ó°ª RA ±wªÌ¤¤§í»s¾¯»P TNF ªýº¢¾¯ªº¤ñ¸û¡C (5.3) • ¸û°ªªº MACE µo¥Í²v¡]©w¸q¬°¤ß¦åºÞ¦º¤`¡B ¤ß¦Ù±ð¶ë©M¤¤·¡^»P¥t¤@ºØ JAK §í»s¾¯ »P RA ±wªÌ¤¤ªº TNF ªýº¢¾¯¬Û¤ñ¡C (5.4) • ±µ¨ü RINVOQ ªvÀøªº±wªÌµo¥Í¦å®ê§Î¦¨¡C ªÍ®ê¶ë¡BÀR¯ß©M°Ê¯ß®ê¶ëªºµo¥Í²v¼W¥[ ¥t¤@ºØ JAK §í»s¾¯»P TNF ªýº¢¾¯ªº¦å®ê§Î¦¨¡C (5.5)
WARNING: SERIOUS INFECTIONS, MORTALITY,
MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS
See full prescribing information for complete boxed warning. • Increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with RINVOQ if serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1) • Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase (JAK) inhibitor vs. tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients. (5.2) • Malignancies have occurred in patients treated with RINVOQ. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3) • Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4) • Thrombosis has occurred in patients treated with RINVOQ. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)
¯SÀ³©Ê¥Öª¢ • 12 ·³¤Î¥H¤WÅé«¦Ü¤Ö 40 ¤½¤ç©M 65 ·³¥H¤Uªº¦¨¦~¤H¡G¶}©l¤fªA 15 mg ªvÀø ¨C¤Ñ¤@¦¸¡C ¦pªG¨S¦³Àò±o¨¬°÷ªºÅTÀ³¡A½Ð¦Ò¼{¼W¥[ ¾¯¶q¬° 30 mg¡A¤fªA¡A¨C¤é¤@¦¸¡C (2.5) • 65 ·³¤Î¥H¤Wªº¦¨¤H¡G±ÀÂ˾¯¶q¬° 15 ²@§J¤@¦¸ Atopic Dermatitis • Pediatric Patients 12 Years of Age and Older Weighing at Least 40 kg and Adults Less Than 65 Years of Age: Initiate treatment with 15 mg orally once daily. If an adequate response is not achieved, consider increasing the dosage to 30 mg orally once daily. (2.5) • Adults 65 Years of Age and Older: Recommended dosage is 15 mg once
Table 13: Efficacy Results of Monotherapy Trials at Week 16 in Patients with Moderate to Severe AD 16¥«¶g¤T´ÁÀø®Ä(°ò½u¥§¡EASI29//IGA0,1=449%)---¥¼¥Î¹L¥Íª«¨î¾¯ªº¤¤-««×AD±wªÌ
1.IGA0,1 ¹êÅç²ÕVS ¹ï·Ó²Õ Trial AD-1 15mg 48% vs 8% 30mg 62% vs 8%
Trial AD-2 15mg 39% vs 5% 30mg 52% vs 5%
Trial AD-3( RINVOQ+TCS VS TCS) 15mg 40% vs 11% 30mg 59% vs 11%
2.EASI75 ¹êÅç²ÕVS ¹ï·Ó²Õ Trial AD-1 15mg 70% vs 16% 30mg 80% vs 16%
Trial AD-2 15mg 60% vs 13% 30mg 73% vs 13%
Trial AD-3( RINVOQ+TCS VS TCS) 15mg 65% vs 26% 30mg 77% vs 26%
¤fªAÀø®Ä¬O¤£¿ù,¥i±¤°Æ§@¥Î¤Ó«. ASLN ¤½¥q 9/15°²³]ASLAN004 ¨C¶g¤@°wÀø®Ä¥i»P RINVOQ® (upadacitinib)¤ñ¸û. RINVOQ®¤T´Á¬O-¥¼¥Î¹L¥Íª«¨î¾¯ªº¤¤-««×AD±wªÌ
Trial AD-3 ¹ï RINVOQ+TCS ,®Ä¯q¤£¤j. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/1 ¤W¤È 10:29:43
²Ä 5730 ½g¦^À³
|
9/15 R&D DAY ir.aslanpharma.com/static-files/d1f92c02-b2af-4f7c-8006-8c9cdcce4c5f
P.38 ASLN004 ¬Û¹ï©óRinvoq (upadacitinib)¤fªAÃÄ--(¦³«¤j°Æ§@¥Î ·ÀI-) ¨Ï¥Î°¾¦n¹ï¤ñ:
2B 75¤H ,¥i¯à¤è®×c: TREK-AD QW(¨C¶g¤@°w) 47%---¤G½uÃĪ«
Rinvoq (upadacitinib) ¥«»ù5600¬ü¤¸/¤ë, °ª©óDupilumab 3300¬ü¤¸/¤ë ¬ù5600/3300=1.7¿
ASLAN004 ¤G½u, ¨C¶g¤@°w*16¶gÀøµ{¶O¥Î©MRinvoq (upadacitinib)¤ñ¥ÎÃĦ¨¥»¥i¦³¬Û·íªºÄvª§¤O.
www.goodrx.com/rinvoq |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/31 ¤U¤È 09:40:12
²Ä 5729 ½g¦^À³
|
aslanpharma.com/app/uploads/2021/05/LB793-Poster_v2-SB2.pdf 1A °·±d¤H¥´¤@°w SC(¥Ö¤Uª`®g) 300mg/600mg ²Õ§¹¥þ§í¨î¥u¦³7¤Ñ. ²Ä14¤Ñ¦³30%/10%ªº¤Ï¼u
°·±d¤H¥´¤@°w IV(ÀR¯ßª`®g) 10mg/KG(60¤½¤ç600mg) ²Õ§¹¥þ§í¨î30¤Ñ
ASLAN004 SC¥Í¦¨²v(¥´¦bªí¥Ö ¶i¤JÀR¯ßÃĶq¤ñ²v)¥i¯à¤£¨ì50%. DUPILUMAB SC¥Í¦¨²v53%.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/31 ¤U¤È 09:26:42
²Ä 5728 ½g¦^À³
|
aslanpharma.com/app/uploads/2021/05/LB793-Poster_v2-SB2.pdf 1A °·¼o±d¤H¥´¤@°w SC 300mg/600mg ²Õ§¹¥þ§í¨î¥u¦³7¤Ñ. ²Ä14¤Ñ¦³30%/10%ªº¤Ï¼u
1b SC 400mg/600mg ¥´§¹°w«á,¨Ì¾ÚTRAC/IgE ¥Íª««ü¼Ð¥i«O4~6¶g©³ÀÉ,¥B±q²Ä¤T¶g¶}©l´N¹F¬Û¹ï§CÂI.
2b SC 300mg/400mg Q2w/0/1/2¶g¦U¥´¤@°w«á±q²Ä4¶g°_¨C¤G¶g¤@°w¨ì²Ä14¶g.¥Íª««ü¼Ðºû«ù¦b©³Àɦ³¾÷·|,¦ý4¶g«án¦A©³¥i¯à¤£·|¤Ó¦h. ¬GÀø®Ä¥i¯à©M8¶g/1-°wªº1b¬Ûªñ.
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c p.24//p.25 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/31 ¤U¤È 09:11:31
²Ä 5727 ½g¦^À³
|
Ó¤H²q°¼: 2b clinicaltrials.gov/ct2/show/NCT05158023 295¤H
Àø®Ä´N¤j¬ùµ¥©ó 1bmITT
EASI75 69% VS24% (¹ï·Ó²Õ)---®t²§55% IGA0,1 45.5% VS 15% (¹ï·Ó²Õ) ---®t²§30.5%(30.5%/28% DUPILUMAB=109%)
¦]¬°2B °w¼Æ9°w ªñ1B 8°w. Àø®ÄÀ³¬Û·í.
ˬO¤G½uÃÄ16¶g16°w, ¤~¦³¾÷·| EASI75 73%//IGA0,1 57%. ¦h7°w¦³¨äÀø®Ä.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/31 ¤U¤È 08:48:25
²Ä 5726 ½g¦^À³
|
9/15 R&D DAY ir.aslanpharma.com/static-files/d1f92c02-b2af-4f7c-8006-8c9cdcce4c5f
P.38 ASLN004 ¬Û¹ï©ódupilumab ¨Ï¥Î°¾¦n: 2B 295¤H .¥i¯à TREK-DX Q4W(°w/4¶g)57% /Q2W(°w/2¶g)47%----¤@½uÃĪ«
2B 75¤H ,¥i¯à¤è®×c: TREK-AD QW(¨C¶g¤@°w) 47%---¤G½uÃĪ«
47%*65%(dupilumab ¤¤Â_²v)=30.55%------¤G½uÃĪ«
¦ô¤»¤ë©³¸Ñª¼¥i¼W¥[¤G½uÃĪ«30.55% +¤@½uÃĪ«47%~57% = 78%~88% ---- --------------------------------------------------- ¤½¥qªºì·N¦p¤W,¨Ì¦¹¨Ó¼W¥[³Q¨ÖÁÊ»ùÈ.
¦ý2023/3¤ë16~26¤é, ¦p¦ó©Ô¹L1¬ü¤¸?§_«hn´î¸ê~
·|¤£·|3¤ëªì¥ý¸Ñª¼«á,¥ý§ä¨p¶Ò°òª÷¬ü¤¸7*80%*88%=4.92¬ü¤¸/ªÑ,6¤ë¤½§G¼Æ¾Ú¥]¾P7*80%=5.6¬ü¤¸/ªÑ
---------------------- ¦p2021¦~2¤ë24¤é¥ý¨p¶Ò3.52¬ü¤¸/ªÑ,1800¸U¬ü¤¸ (3.52/4=88%) ir.aslanpharma.com/static-files/8e211cfa-512e-4f27-b382-dea0efcc2e14
2021/3¤ë1¤éªì¤½§G´Á¤¤¸Ñª¼
2021/3¤ë4¤é«á¥]¾P4¬ü¤¸/ªÑ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/31 ¤U¤È 08:07:47
²Ä 5725 ½g¦^À³
|
9/15·s»Dº` ASLAN Pharmaceuticals ±Ò°ÊÁ{§Ép¹º¥H¬ã¨s Eblasakimab ¦b Dupilumab ¸g¾úªº¯SÀ³©Ê¥Öª¢±wªÌ¤¤ªº§@¥Î
ASLAN p¹º©ó 2022 ¦~²Ä¥|©u«×¶}©l TREK-DX¡]EblasaKimab ¦b Dupilumab eXperienced AD ±wªÌ¤¤ªº¸ÕÅç¡^¡A¥Hµû¦ô eblasakimab §@¬°´À¥N¥Íª«»s¾¯¹ï¤w°±¤î¨Ï¥Î dupilumab ªvÀøªº¯SÀ³©Ê¥Öª¢ (AD) ±wªÌªºÀø®Ä©M¦w¥þ©Ê
TREK-DX ±N¬ã¨s eblasakimab ¦b±µ¨ü¹L dupilumab ªvÀøªº±wªÌ¤¤ªº¼ç¦b¥Î³~¡A¥H¸É¥R¥¿¦b¶i¦æªº TREK-AD ¸ÕÅç¦b¥Íª«¤Ñ¯uªº±wªÌ¤¤¶i¦æ ¨â¶µ¬ã¨sªºµ²ªG¥i±N¨Ì¥¬©Ô¦è³æ§Ü©w¦ì¬°ªvÀø¤¤«×¦Ü««× AD ªºº¿ï¥Íª«»s¾¯ ------------------------------ (TREK-DX²Ä¤@¦ì¹wp¦~©³©Û¶Ò//¥þ¬°(¥_¬ü±wªÌ2:1,¦ô³Ì¦h25©Û¶ÒÓ¤¤¤ß) --¦ô2023¦~6¤ë©³TREK-DX 75¤H ¸Ñª¼//¦P®É¤½§GTREK-AD 2B 295¤H,¸Ñª¼³ø§i) ------------------------------
ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in atopic dermatitis (AD) patients who have discontinued treatment with dupilumab TREK-DX will study the potential use of eblasakimab in patients that have been treated with dupilumab, complementing the ongoing TREK-AD trial in biologic naïve patients Results from both studies could position eblasakimab as the preferred first-choice biologic for the treatment of moderate-to-severe AD TREK-DX program is part of the Company¡¦s existing operating plan and has no impact on previously-reported cash runway Further discussion of TREK-DX will take place during the Company-hosted R&D Day on September 15, 2022 California and Singapore, September 14, 2022 ¡V ASLAN Pharmaceuticals (¡§ASLAN¡¨, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to initiate a new clinical trial of eblasakimab for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with dupilumab. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile. ASLAN expects to enroll the first patient in the trial in the fourth quarter of 2022.
¡§In contrast to our Phase 2b trial in biologic naïve patients, TREK-DX will allow us to evaluate eblasakimab¡¦s unique mechanism of action in a new patient population,¡¨ said Dr Carl Firth, CEO, ASLAN Pharmaceuticals. ¡§We believe that many patients previously treated with dupilumab can benefit from eblasakimab, and this data could support the use of eblasakimab in both the biologic naïve and experienced patient populations.¡¨
The TREK-DX trial is expected to enroll 75 patients in a randomized, double-blind, placebo-controlled, multicenter trial in North America to evaluate the efficacy and safety of eblasakimab in patients with moderate-to-severe AD previously treated with dupilumab. The trial will enroll patients who have discontinued dupilumab treatment for any reason, including inadequate control of AD, loss of access or an adverse event. The program is part of the Company¡¦s existing operating plan and has no impact on its previously-reported cash runway.
The trial will consist of a 16-week treatment period and a 12-week safety follow-up period. The primary efficacy endpoint is percentage change in Eczema Area Severity Index (EASI) score from baseline to week 16. Key secondary efficacy endpoints include the proportion of patients achieving Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear), proportion of patients with a 75% or greater reduction in EASI (EASI-75), proportion of patients achieving EASI-50 and EASI-90, and changes in peak pruritus.
¡§Dupilumab has played an important role in demonstrating the benefits of targeting the IL4/IL-13 signaling pathway in AD. However, some patients do not demonstrate an optimal or sustained response to dupilumab, or develop adverse events such as conjunctivitis, and thus seek an alternative treatment option that could offer an improved safety and efficacy profile,¡¨ said Dr Alex Kaoukhov, CMO, ASLAN Pharmaceuticals. ¡§As we have seen in other indications, such as psoriasis, targeting different molecular components of the same signaling pathway can lead to different clinical outcomes and we believe that eblasakimab¡¦s unique approach to blocking the Type 2 receptor may offer an effective treatment for dupilumab-experienced patients.¡¨
ASLAN is also conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of eblasakimab in adult patients with moderate-to-severe AD who are candidates for systemic therapy. Topline data from this trial is expected in the first half of 2023.
ASLAN¡¦s management is hosting a Research and Development (R&D) Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York. To attend the event in person or virtually, please click here for registration. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN Pharmaceutical¡¦s website at ir.aslanpharma.com/
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/31 ¤U¤È 07:49:37
²Ä 5724 ½g¦^À³
|
¬ü°ê¤G¤jú³°Ó³Ì·sºû«ùASLN ºû«ù¶R¶iµûµ¥ ¥Ø¼Ð»ù 7~4 ¬ü¤¸.
1.H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Aslan Pharmaceuticals (ASLN ¡V Research Report) today and set a price target of $7.00. The company¡¦s shares closed last Friday at $0.40.
H.C. Wainwright Sticks to Their Buy Rating for Aslan Pharmaceuticals (ASLN)
Oct 31, 2022, 06:15 PM
www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-aslan-pharmaceuticals-asln?mod=mw_quote_news
2. ASLN 12:29 10/28/22 Aslan Pharmaceuticals ended Q3 with $69M in cash, says Piper Sandler Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $4 price target on Aslan Pharmaceuticals shares.
Aslan is conducting the Phase IIb TREK-AD study of eblasakimab in ~300 moderate-to-severe atopic dermatitis with top-line data expected in 2Q23, and the company ended Q3 with cash of $69M, Tenthoff tells investors in a research note. Aslan is also planning a Phase II study of DHODH inhibitor farudodsta in skin autoimmune disease that will commence in 1H23, the analyst adds.
Read more at: thefly.com/n.php?id=3605306 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/28 ¤U¤È 11:32:53
²Ä 5723 ½g¦^À³
|
¤Ñ©R¤j¡A
¦pªG¨ì©ú¦~3¤ë26¤é«e¡A004 2b¹êÅç¼Æ¾Ú¦nÃa¡A¾ã²z²Îp¸ê®Æ®É¡AÀ³¸Ó¦´N¤ß²z¦³¼Æ
YªÑ»ù¤´¥¼¯à³sÄò¯¸¤W1¬ü¤¸¡A¥Nªí¤jªÑªF¤Îªk¤H¤w¤£»{¦P¸Ó¤½¥q¡A¤£Ä@¦A¼W¸ê¡C
§Ú»{¬°¦Ñ·à°_¦º¦^¥Íªº¾÷·|¤w·L¥G¨ä·L¡A©¡®É¥u¯à©ñ±ó»{¿é
¦Û¤vªº¤½¥q¦Û¤w¤£±Ï½Ö·|±Ï¡A¤j®a¥u¯à©ñ±ó©ñ¥Í
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/28 ¤U¤È 10:18:06
²Ä 5722 ½g¦^À³
|
³¯¤j¡A
½Ðª`·N¡A©ú¦~3¤ë26¤é«eYªÑ»ù¥¼³sÄò¯¸¤W1¬ü¤¸¡C
¥Bn«ùÄò¤W¥«¡C
ASLN ¤½¥q¤èªk 1¡A´î资 2.¼W¥[ìªÑ¹ï´«ADR¤ñ²v¡C
¥Ø«e¤½¥q¡A2bªº¸Ñª¼资®Æ¤½§G¤é´Á¦ô¦b2023¦~²Ä¤G©u¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥i¯à¤]µL´Á¤¤³ø§i¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/28 ¤U¤È 09:40:11
²Ä 5721 ½g¦^À³
|
¬ü°êªF³¡®É¶¡ 2022 ¦~ 10 ¤ë 28 ¤é 07:00 | ¸ê®Æ¨Ó·½¡G ¨È´µÄõÃÄ·~¦³¤½¥q
... ºI¦Ü 2022 ¦~ 9 ¤ë 30 ¤é¡A¤½¥q¥H 6,890 ¸U¬ü¤¸ªº²{ª÷¡B²{ª÷µ¥»ùª«©Mµu´Á§ë¸êºû«ù°·±dªº¸gÀ窬ªp¡F¹wp¨ì 2023 ¦~©³ªº¶]¹D ¬ã¨s eblasakimab ¦bdupilumab¤¤ªº¼ç¤Oªº·s TREK-DX Á{§Ép¹º¸g¾ú¤F¯SÀ³©Ê¥Öª¢ (AD) ±wªÌ¡A¦³±æ¦b 2022 ¦~©³«e©Û¶Ò²Ä¤@¦ì±wªÌ eblasakimab¦b¥Íª«¥®¸X¤¤«×¦Ü««× AD ±wªÌ¤¤ªº 2b ´Á TREK-AD ¸ÕÅ祿¦b¶i¦æ¤¤¡A¹wp±N¦b 2023 ¦~²Ä¤G©u«×²£¥Í¤@½u¼Æ¾Ú ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2022 ¦~ 10 ¤ë 28 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN) ¬O¤@®aÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬°]°ÈºI¦Ü 2022 ¦~ 9 ¤ë 30 ¤éªº²Ä¤T©u«×·~ÁZ¡A¨Ã´£¨Ñ¤F³Ìªñ¤½¥q¬¡°Êªº³Ì·s±¡ªp¡C
¡§¦b²Ä¤T©u«×¡A§ÚÌ´Neblasakimab¦b¯«¸g¤¸æ±Äo©Mª¢¯g³q¸ô¤¤ªº¤£¦P§@¥Î¾÷¨î´£¥X¤F³\¦h·sªº«n¨£¸Ñ¡A¥H¤Î»Pæ±Äo©MºÎ¯v³à¥¢¬ÛÃöªº AD ±wªÌªº¼ç¦b§ïµ½¡A³o³q±`¬O³o¨Ç±wªÌ¡A¡¨ ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤h¤À¨É¹D¡C¡§§ÚÌ´Á«Ý 2b ´Á¼Æ¾Ú¦b 2023 ¦~²Ä 2 ©u«×¦b¥Íª«¤Ñ¯u¤¤«×¦Ü««× AD ±wªÌ¤¤µû¦ôeblasakimabªº¥Dn¼Æ¾Ú¡C¦b§Ú̱N±q TREK-AD ©M TREK-DX ¥Í¦¨ªº·s¼Æ¾Ú¤§«e¡A§ÚÌ¥¿¦b±q¥¿¦b¶i¦æªº¬ã¨s¦X§@¤¤«Ø¥ß¤@®M±j¦³¤Oªº¨£¸Ñ¡A³o¨Ç¦X§@±N©ó©ú¦~ªì®i¥Ü¡A¥H¤ä«ùeblasakimab¨ã¦³§@¬°¤¤««× AD ªº®t²§¤ÆªvÀøªº¼ç¤O¡A¦b 2 «¬ÅX°Êªºª¢¯g©Ê¯e¯f¤¤¨ã¦³¼sªxªºªvÀø¼ç¤O¡C¡¨
2022 ¦~²Ä¤T©u«×¤Îªñ´Á·~°È«GÂI
¨Ì¥¬©Ô»ô³æ§Ü
8 ¤ë¡A¤½¥q»P Belle.ai ñ¸p¤F¤@¶µ³\¥i¨óij¡A¥Î©ó¦b¥þ²y¦hÓ¯¸ÂI¨Ï¥Î belleStudy ™¼Æ¦r¹Ï¹³®·Àò³n¥ó¡A¥Î©ó AD ¤¤¥¿¦b¶i¦æªºeblasakimabªº TREK-AD ¬ã¨s¡C©ö©ó¨Ï¥Îªº¸Ñ¨M¤è®×¥i¥H³q¹L¹Ï¹³®·Àò¼Ð·Ç¤Æ°O¿ý AD ¯e¯fÄY«µ{«×µû¤À¡A¸Ó§Þ³N±N¨Ï ASLAN ¯à°÷¶i¤@¨B¥[±j¨ä¦b TREK-AD ¬ã¨s¤¤ªº½è¶q±±»sµ{§Ç¡C 9 ¤ë¡A¦b²Ä 31©¡¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç·| (EADV) ¦~«×¤j·|¤W®i¥Ü¤F¤T±i®ü³ø¡A¨ä¤¤¥]§t¥ý«e³ø§iªºeblasakimab 1b ´Á·§©ÀÅçÃÒ¸ÕÅ窺¥Íª«¼Ð»xª«¡BÀø®Ä´ú¶q©M±wªÌ³ø§iªºµ²ªG´ú¶qªº·s¼Æ¾Ú¡C¼Æ¾ÚÅã¥Üeblasakimab§í¨î AD ªº¤U´åª¢¯g¥Íª«¼Ð»xª«¡A¨Ã¥B³oºØ§@¥Î¦b³Ì«á¤@¦¸µ¹ÃÄ«á«ùÄò 4 ¨ì 6 ¶g¡C±µ¨üeblasakimabªvÀøªº±wªÌ¦bºÎ¯v½è¶q´ú¶q©MeblasakimabªvÀø¤è±ªí²{¥XÅãµÛ§ïµ½»P¦w¼¢¾¯¬Û¤ñ¡AP-NRS¡]Äo¡^µû¤À°§C¡A¦b©Ò¦³¾¯¶q²Õªº¤K©PªvÀø¹Lµ{¤¤³£¦³§ïµ½¡C®ü³ø¥i¦b¤½¥qºô¯¸ªº·s»D©M¥Xª©ª«³¡¤À§ä¨ì¡C 9 ¤ë¡A¤½¥q¶}©l¤F TREK-DX¡]EblasaKimab ¦b Dupilumab eXperienced AD ±wªÌ¤¤ªº¸ÕÅç¡^¡A³o¬O¤@¶µ¬ã¨seblasakimab¦bdupilumab¤¤«×¦Ü««× AD ±wªÌ¤¤ªº·sÁ{§É¸ÕÅç¡C¸Ó¸ÕÅç¥]¬A 16 ¶gªºªvÀø´Á©M 12 ¶gªº¦w¥þÀH³X´Á¡C¥DnÀø®Ä²×ÂI¬OÀã¯l±¿nÄY««×«ü¼Æ (EASI) µû¤À±q°ò½u¨ì²Ä 16 ¶gªº¦Ê¤À¤ñÅܤơCµ²¦X TREK-AD ¸ÕÅ礤¥Íª«ªì©l AD ±wªÌªº¼Æ¾Ú¡A§Ú̬۫H TREK-DX ¬ã¨sªºµ²ªG¦b¦³¥Íª«¾Ç¸gÅ窺¤H¸s¥i¥H±Neblasakimab©w¦ì¬°¤¤«×¦Ü««× AD ªºº¿ïº¿ïªvÀø¤èªk¡C ¤½¥q©ó 9 ¤ëÁ|¿ì¤F¬ãµo¤é¬¡°Ê¡AºÞ²z¼h¦b·|¤W¥þ±§ó·s¤Feblasakimab¶}µop¹º¡C¦è¥_¤j¾Ç Feinberg Âå¾Ç°|ªº Peter A Lio ³Õ¤h©M¬ù¿«ÀN´¶ª÷´µ¤j¾Çªº Shawn Kwatra ³Õ¤h°Q½×¤F AD ©M 2 «¬ÅX°Ê¯e¯f¤¤·s¥X²{ªº¥¼º¡¨¬»Ý¨D¡BªvÀø«e´º©M¼ç¦bªº¤À¤l¾÷¨î¡C¥i¥H¦b¤½¥qºô¯¸ªº§ë¸êªÌÃö«Y³¡¤À§ä¨ì¬¡°Ê©Mºt¥Ü§÷®Æªº«¼½¡C 9 ¤ë¡A¤½¥q¦b¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¨ó·| (ESDR) ¦~·|ªº³Ì·s·|ij¤W®i¥Ü¤Feblasakimabªº·sÂà¤Æ¼Æ¾Ú¡C»P Shawn Kwatra ³Õ¤h©M Madan Kwatra ³Õ¤h¥¿¦b¶i¦æ¦X§@ªº²Ä¤@§å¼Æ¾ÚÅã¥Ü¡AAD ±wªÌ¥Ö½§¼Ë¥»¤¤ªÎ¤j²ÓM©M¶Ý»Ä©Ê²É²ÓMªº IL-13R£\1 ªí¹F¼W¥[¡A±q¦Ó¥[±j¤F IL-13R£\1 ¦b AD ¤¤ªº®Ö¤ß§@¥Î¡C¦b¤HÃþ¯«¸g¤¸¼Ò«¬¤¤¡A¨Ì¥¬©Ô°ò³æ§Ü ÅãµÛ°§C¤F¥Ñ¤£¦Pªº IL-4 ©M IL-13 æ±Äo³~®|¤Þ°_ªº¯«¸g¤¸æ±Äo±Ó·P©Ê¡A¨Ã¥BÁÙ½T©w¤F IL-13R£\1 «H¸¹¶Ç¾É¦b¤¶¾É AD ¤§¥~ªº¯«¸g¤¸¿³¾Ä©Ê©M±Ó·P©Ê¤¤ªº·s§@¥Î¡C ªk¾|¹F (ASLAN003)
¥Ö½§¦Û¨§K¬Ì©Ê¯e¯fªºÁ{§É¶}µop¹º¥¿¦b³Ì«áºV©w¡A¹wp 2023 ¦~¤W¥b¦~¶}©l¶i¦æ 2 ´Á¸ÕÅç¡C ¹wp§Y±N¨ì¨Óªº¨½µ{¸O
¨ì 2022 ¦~©³¡A²Ä¤@¦ì±wªÌ°Ñ¥[¤F TREK-DX ¸ÕÅç¡C ¬ð¥Xeblasakimab§@¥Î¾÷¨î¿W¯S§@¥Îªº·sÂà¤Æ¼Æ¾Ú±N©ó 2023 ¦~ªì¤½§G¡C eblasakimab 2b ´Á TREK-AD ¸ÕÅ窺¤@½u¼Æ¾Ú¹wp±N©ó 2023 ¦~²Ä¤G©u«×µo¥¬¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/28 ¤U¤È 07:50:24
²Ä 5720 ½g¦^À³
|
ASLAN Q3°]³ø¤Î资°T§ó·s¡C finance.yahoo.com/news/aslan-pharmaceuticals-reports-third-quarter-110000300.html
¦Ü 2022 ¦~ 9 ¤ë 30 ¤é¡A¤½¥q¥H 6,890 ¸U¬ü¤¸ªº²{ª÷¡B²{ª÷µ¥»ùª«©Mµu´Á§ë¸êºû«ù°·±dªº¸gÀ窬ªp¡F ¹wp¨ì 2023 ¦~©³ªº¶]¹D
¬ã¨s eblasakimab ¦b dupilumab ¤¤ªº¼ç¤Oªº·s TREK-DX Á{§Ép¹º¸g¾ú¤F¯SÀ³©Ê¥Öª¢ (AD) ±wªÌ¡A¦³±æ¦b 2022 ¦~©³«e©Û¶Ò²Ä¤@¦ì±wªÌ
eblasakimab ¦b¥¼¸g¥Íª«ªv¾¯¹Lªº¤¤«×¦Ü««× AD ±wªÌ¤¤ªº 2b ´Á TREK-AD ¸ÕÅ祿¦b¶i¦æ¤¤¡A¹wp±N¦b 2023 ¦~²Ä¤G©u«×²£¥Í¤@½u¼Æ¾Ú¡C
Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022; expected runway through late 2023
New TREK-DX clinical program studying eblasakimab¡¦s potential in dupilumab experienced atopic dermatitis (AD) patients on track to enroll first patient by the end of 2022
The Phase 2b TREK-AD trial for eblasakimab in biologic naïve moderate-to-severe AD patients is on track and anticipated to generate topline data in Q2 2023 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/28 ¤W¤È 06:59:40
²Ä 5719 ½g¦^À³
|
³¯¤j¡A
¦]ªG¤£¬N¡A 随缘¤£ÅÜ¡A ¤£ÅÜ随缘¡C
11¤ë¤¤¦¯¡A¤½¥¬Q3°]³ø¡A¦ôp·|«Å¥¬2b ¦¬®×§¹¦¨¡C
¦ô©ú¦~2¤ë¤¤¦¯-3¤ë¤W¦¯¸Ñª¼¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/28 ¤W¤È 12:03:09
²Ä 5718 ½g¦^À³
|
¤Ñ©R¤j
¦p²Ä2°¦¸}¤£¯}«e§C¡A¤S¥X¤j¶q¡A§Û©³¥i¦æ¶Ü¡A ·Pı°÷«K©y¤F¡A¦n¹³¾À¯È¤@¯ë
·Q¤F¸Ñ±zªº¬Ýªk |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/27 ¤U¤È 11:49:18
²Ä 5717 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/10/27 ¤U¤È 07:43:41
²Ä 5716 ½g¦^À³
|
³q±`¥¢±Ñ¹Lªº¤½¥q¡A«ÜÃø¯¸±o°_¨Ó ¦ý¯¸±o°_¨Óªº¤½¥q¡A³q±`¦n¹B¨ì¤F ¥[ªo¡I¨È·àÅܶ¯·à¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/10/27 ¤U¤È 06:13:00
²Ä 5715 ½g¦^À³
|
ªÑ»ù¤w¸g®z¶Õ¨ì¹³³Q©ñ±ó¤@¼Ë §Ú¤w¸g¤£´Á«Ý¸Ñª¼¦³¤°»ò¥i¯à¤F ´N¥áµÛ·í¼Ö³z¡A¤[¤[¨Óª©¤W¬Ý¤@¤U |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/27 ¤U¤È 04:52:53
²Ä 5714 ½g¦^À³
|
³¯¤j¡A
°²³] ªñ¦ü Lebrikizumab 2b Àø®Ä
clinicaltrials.gov/ct2/show/results/NCT03443024
1.IGA0,1 ¹ï·Ó²Õ=15.3%
4¶g¤@°w 125mg =22.6% p=0.1917(pÈ>0¡P05¡^ 4¶g¤@°w 250mg=33.7% p=0.0392(¤T´Á°µ¬°18¡ã52¶g©µªøªvÀø¤§¤@¡A¨ÃµL1¡ã16¶gªvÀø³]p¡^ 2¶g¤@°w 250mg=44.6% p=0.0023
2¡PEASI75 ¹ï·Ó²Õ=24.3%
4¶g¤@°w 125mg =43.3% p=0.0610(pÈ>0¡P05¡^ 4¶g¤@°w 250mg=56.1% p=0.002)¤T´Á°µ¬°18¡ã52¶g©µªøªvÀø¤§¤@¡A¨ÃµL1¡ã16¶gªvÀø³]p¡^ 2¶g¤@°w 250mg=60.2% p=0.0005
280¤H¤@4²Õ¡A58Ó¤¤¤ß¡A¥§¡4.82¤H¡þ¤¤¤ß
¥H¤W³]p¡A§Y¨Ï¦³¨CÓ¤Hªº¨C¤G¶g¸ê®Æ¡A¦pªGµL¸Ñª¼¡A¬Ý¤£¥X¨C²ÕªºÀø®Ä¡C
ASLAN004 2b ¡A§ó¦h²Õ¦@5²Õ¡A°²³]295¤H¡þ65¤¤¤ß¡×4¡P5¤H/¤¤¤ß⋯⋯ ¥¼¸g¸Ñª¼¹ê¬Ý¤£¥X¡A¦U²ÕªºÀu¦H¡C
¸Ñª¼¤è¯àª¾±x¡A¦U²ÕpÈ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/27 ¤U¤È 12:14:49
²Ä 5713 ½g¦^À³
|
ir.aslanpharma.com/static-files/60a95013-835e-4341-9b3b-270ce73b9b1d
2022/Q2 ASLN °]³ø¡A¦p¤W
²bÈ3200¸U¬ü¤¸ ·l¯q-1300¤d¸U¬ü¤¸¤@Q2 ²{ª÷7800¸U¬ü¤¸
¨ì2022/Q4. ²bȦô³Ñ600¸U¬ü¤¸ ²{ª÷¦ô³Ñ5200¸U¬ü¤¸¡C¡]¨C©u·l¥¢1300¸U¬ü¤¸¡^
finance.yahoo.com/quote/ASLN/?p=ASLN
ASLN ¦¬½L¥«È3080¸U¬ü¤¸¡C ¤@¤@¤@¤@
ASLN¤½¥qªÑ»ù¡A¥Ø«e¥H¥]¾P¨é°Óªº¦ôȳ̷ǽT¡C
2b ¸Ñª¼¼Æ¾Ú¡AY¦p¹w´Á¡]¦p 1bmITT EASI 69%/IGA 44%),¥Ø¼Ð»ù7¬ü¤¸¡A¤U¦¸¥]¾P»ù5¡D6¬ü¤¸¡þªÑ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/10/27 ¤W¤È 11:58:04
²Ä 5712 ½g¦^À³
|
Á`ı±o¥Ø«e¦Ñ·àªºªÑ»ù¡A¤£¹³¬O¸Ñª¼ªºµ²ªGn¶W¶V§ù¥²ª¢¤ÎLebrikizumabªº¼ËºA¡A§Y¨Ï¸Ñª¼¸õ¤W5¿¡A¤]¥u¦³2.25¡A¥u¬O¤£´î¸ê¦Ó¤w¡A«ÂI¬OCEOn§V¤O¤@ÂI¡A¦h«µøªÑ»ù¡A¤£µM´«ð¾÷ºc¨Ó¸gÀç¤]¤£¿ù¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/27 ¤W¤È 11:57:57
²Ä 5711 ½g¦^À³
|
³¯¤j¡A
¥H¤UÓ¤HÆ[¹î¡C
¬ü°ê¤p«¬·sÃĪѪºªÑ»ùªº¥«È±`¦b¥¼¨úÃĵý®É±µªñªÑ²¼²bÈ¡C
¨ú±oÃĵý«á3Ӥ몺¥«È¬ù©Ô°ª¨ì¡C¥«³õ»{¥i¦y®p¾P°âÃBx3¿¡C
³Q¨ÖÁÊ»ùÈ=¨C¦~Àç·~²bȪº§é²{È
¡]¦pLebrikizumab 2019¦~©³¦©°£¼Ú¬w°Ï¾P°â¡A¤W¥«²Ä5¦~³Ì°ª¾P°â15»õ¬ü¤¸¡A¨CÀç·~§Q¯q§é²{11»õ¬ü¤¸¡^¡A³Ì«á11»õ¬ü¤¸³Q¨ÖÁÊ¡C
¨ÖÁʤ½¥q¥i¦b²bȪº°ò¦¤WÀò¤T¿¥H¤WªÑ»ù³ø¹S¡C
¤½¥q¥DºÞ¥Dn¦¬¤J¡A¬Ò¾aªÑ²¼¤À¬õ¡A¬ü°ê¤½¥q¤ÀªÑ§Q½Òµ|«¡A©Ò¥H¦hªº¸êª÷¬Ò¶R¤½¥q®wÂêѡC
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/27 ¤W¤È 10:07:10
²Ä 5710 ½g¦^À³
|
CNTB¤½¥qCBP201 AD 2b ¸Ñª¼¤ê(²q2021/07/28)¡A ªÑ»ù¦b°ªÀÉ23-28¬ü¤¸¡A11¤ë19¤é¤½¥¬¸Ñª¼¼Æ¾Ú¡A·í¤é³Ñ4¬ü¤¸¦h¡C
DERM¤½¥q Lebrikizumab AD 2b ¸Ñª¼/·í¤é(2019/02/07)¤½¥¬¡C
ªÑ»ù¦b§CÀÉ6¶ô¦h¬ü¤¸¡A¸Ñª¼·í¤é¤jº¦约¤@¿¨ì12¬ü¤¸¥ª¥k¡C 2019¦~10¤ë¶}©l¤T´ÁADÁ{§É¡AªÑ»ù¦^¨ì©³ÂI6¬ü¤¸¥ª¥k¡C
2019¦~12¤ë 18¬ü¤¸¦h/ªÑ¡A³Q§¨Ó¤½¥q«Å¥¬¨ÖÁÊ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/27 ¤W¤È 10:05:17
²Ä 5709 ½g¦^À³
|
¤Ñ©R¤j ·PÁ±zªº¦^´_
¥i¯à¬O¥xªÑ¤º½u¥æ©ö¤ÓÄY« Á`»{¬°ªÑ²¼¤H¬°¾Þ±±ªº¦]¯À·¥¤j
ªÑ»ù¨«¶Õ·|¥ý¤Ï¬M¤½¥q¥¼¨Ó¡A¦]¬°¦³¤H¤w¥ýª¾¹D
©Ò¦³»{¬°004 2b¼Æ¾Ú¥i¯à¤£¨Î
±z»¡ªº¨º®a¤½¥qªÑ»ù³Ì§C¨ì6.6¤¸ ±q¥¼ªø´Á§C©ó1¤¸¡A¦³¤U¥«¦M¾÷
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/27 ¤W¤È 09:42:18
²Ä 5708 ½g¦^À³
|
³¯¤j¡A
www.clinicaltrials.gov/ct2/show/NCT04444752?term=NCT04444752&draw=2&rank=1
CBP 201 AD, 2b 2021/7/28 ¥Dn资®Æ(16¶gªº«ü¼Ð)¡C
¥LªºªÑ»ù¡A¦³³s°Ê²{¶H¡C
finance.yahoo.com/quote/CNTB/
2021/08/10 ³Ì°ª©Ô¤W28¬ü¤¸¡C
(2021/7/28 ¥i¯à¤w¸Ñª¼¡H¡H¡H) 2021/11/19 ¤½§G¼Æ¾Ú ·í¤é³Ñ4¶ô¦h¬ü¤¸¡C
¿éŦb¸Ñª¼¤é¤§«á¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/27 ¤W¤È 09:16:58
²Ä 5707 ½g¦^À³
|
004 2b¸ÕÅç ±q8¤ë26¤é«á¡A
§YµL¥ô¦ó¶i«×§ó·s¸ê®Æ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/27 ¤W¤È 09:12:50
²Ä 5706 ½g¦^À³
|
³¯¤j¡A
DERM (Lebrikizumab )
2019/02/07 AD2b ¸Ñª¼ 2019/02/12 ¼Ú¬w°Ï±ÂÅv
DERM ªÑ»ù¨«¶Õ¡A¦p¤U
www.netcials.com/stock-price-chart-history-nasdaq/DERM-Dermira-Inc/
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/27 ¤W¤È 08:59:42
²Ä 5705 ½g¦^À³
|
¤Ñ©R¤j
³Ìªñ¦³¤°»ò§QªÅ
¬°¦óªÑ»ù¤´«ùÄò¨«§C ²@µL¤î¶^¸ñ¶H ¬O§_¥i¯à¬O004 2b¼Æ¾Ú¤w¦³¤H¥ýª¾¹D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/22 ¤U¤È 12:27:00
²Ä 5704 ½g¦^À³
|
×¥¿-1 ASLAN004 1b mITT¡]8¶gªvÀø¡^ vs 2b ITT´Á±æÈ ¡]16¶gªvÀø¡^//¹ï·Ó²Õ´Á±æÈ¡]16¶g¡^//(¦©°£¹ï·Ó²Õ«áPk¡^
EASI75 =69% vs 73%// ¹ï·Ó²Õ24%//(®t²§ 45% vs 49%)---×¥¿-1(¤¤Â_²v3/16,¥i¯à¤Uרì1/16.¨ì®É¥i¯à¦A©Ô¤ÉEAS75 ¨ì80%¥H¤W¾÷²v¤£¤p)
IGA0¡A1 =44% vs 57%//¹ï·Ó²Õ15%//¡]®t²§ 29% vs 42%)
¤@¤@¤@¤@¤@¸g16¶gªvÀø«áIGA0,1 ·|¦A´£°ª¡A¦pLebrikizumab 2b/ph3 EASI75 ©MIGA0,1®t¶Z16%¡]16¶g¡^
Lebrikizumab 2b//ph3 ¦P¼Ë¼vÅTIL13a1,Àø®Ä§ó¦³°Ñ¦Ò»ùÈ¡A¥u¬OASLAN004 ®Ä²v§ó§Ö¡C ¤@¤@¤@¤@16¶gªº¹ï·Ó²ÕÀø®Ä°Ñ¦ÒLebrikizumab 2b¸ê®Æ¡A¦ôp°ò缐EASI¦b25.5~27.5¤ô·Ç¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/22 ¤W¤È 11:59:53
²Ä 5703 ½g¦^À³
|
¨È·à±dªºì©lªÑ¥»500¡A000¤dªÑ//ADR100¡A000¤dªÑ¡C
Y¤£©Ô°ªªÑ»ù¨ì18.5¬ü¤¸¥H¤W¡A¦ôp¤£¨¬¶Ò¨ì3´ÁÁ{§É4»õ¬ü¤¸ªº¸êª÷¡C
»Ý¦A¥l¶}ªÑªF·|ÂX¼W¸ê¥»ÃB¡C¦ôp¦Ü¤Ö¼W¥[¨ì50%¡A¼W¥[¨ìADR150¡A000¤dªÑ
75¡A000¤dªÑx7¤¸x80%x97%=¬ù4»õ¬ü¤¸¡]·í®ÉDERM AD2b¸Ñª¼«áªº¸êª÷¦s¶q¡^ ¤@¤@¤@¤@
¥t¤@¤è¦¡´N¬O©Ô°ªªÑ»ù¨ì18.4¬ü¤¸¥H¤W
18.4x80%X97%=14.28¬ü¤¸
4»õ¬ü¤¸/14.28=28,000¤dªÑADR¡]¤£¥Î¦AÂX¥RªÑ¥»¡^
¥«È©Ô¤É¦Ü15~18.5»õ¬ü¤¸¥H¤W¡A¦p¦¹³Q¨ÖÁÊ»ù¦A¤@¿40»õ¬ü¤¸§ó¦n½Í¡C
¤½¥qn¥[ªo³á¡ILebrikizumab AD ³Ì°ª¾P°â¤w«O¦u¦ô¨ì45»õ¬ü¤¸¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/22 ¤W¤È 11:27:51
²Ä 5702 ½g¦^À³
|
¤½¥qªº´XÓ1bªº´Á¥Z¸ê®Æ¨¬¥H°µ¬°±ÂÅv«eªº¸ê®Æ°Ñ¦Ò¡G aslanpharma.com/news/?cat=publications
¦p±ÂÅv½Í§P¡A±N¨Ì¾Ú¸Ñª¼¼Æ¾Ú¨Ó©w»ùÈ¡C ¤è®×¥i¥ý°²³] A¡DÀø®Ä¦P1b mITT ®Éªº¥«Ô·»ùÈ¡H¡]¼ç¦b¦y®p¾P°â¡þ²{ª÷§é²{È¡^ B¡BÀø®Ä°ª©ó 1b mITT®Éªº¥«³õ»ùÈ¡H¡]¡§¡^
µ¥¸Ñª¼¦A·L½Õ»ùÈ¡C
Æ¿¤@¤@¤@¤@
ASLAN004 1b mITT¡]8¶gªvÀø¡^ vs 2b ITT´Á±æÈ ¡]16¶gªvÀø¡^//¹ï·Ó²Õ´Á±æÈ¡]16¶g¡^//(¦©°£¹ï·Ó²Õ«áPk¡^
EASI75 =69% vs 73%// ¹ï·Ó²Õ24%//(®t²§ 45% vs 59%)
IGA0¡A1 =44% vs 57%//¹ï·Ó²Õ15%//¡]®t²§ 29% vs 42%)
¤@¤@¤@¤@¤@¸g16¶gªvÀø«áIGA0,1 ·|¦A´£°ª¡A¦pLebrikizumab 2b/ph3 EASI75 ©MIGA0,1®t¶Z16%¡]16¶g¡^
Lebrikizumab 2b//ph3 ¦P¼Ë¼vÅTIL13a1,Àø®Ä§ó¦³°Ñ¦Ò»ùÈ¡A¥u¬OASLAN004 ®Ä²v§ó§Ö¡C ¤@¤@¤@¤@16¶gªº¹ï·Ó²ÕÀø®Ä°Ñ¦ÒLebrikizumab 2b¸ê®Æ¡A¦ôp°ò缐EASI¦b25.5~27.5¤ô·Ç¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/22 ¤W¤È 09:38:00
²Ä 5701 ½g¦^À³
|
°²³] ¨Ì¾ÚDERM ¤½¥qLebrikizumab AD 2b,2019/02/07¸Ñª¼,02/12¼Ú¬w°Ï°Ó·~¤ÆÅv¤O±ÂÅv.
ASLAN004
2022¦~10¤ë15¤éASLAN004 2¤ë, ¤w¦¬§¹³Ì«á¤@¤H¥B¥´²Ä¤@°w. 2023¦~2¤ë15¤é¸Ñª¼ 2023¦~2¤ë16¤é¶Ò¸ê(¨p¶Ò/¥]¾P)3~5»õ¬ü¤¸,·Ç³Æ°µ¤T´Á. 2023¦~2¤ë22¤é¼Ú¬w°Ï°Ó·~¤ÆÅv¤O±ÂÅv.
²{¦b¤½¥qÀ³¸Ó¦b°µ¦ó¨Æ? À³¸Ó«Ü¦£!!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/19 ¤W¤È 08:06:35
²Ä 5700 ½g¦^À³
|
Pk
1.Lebrikizumab 2b clinicaltrials.gov/ct2/show/results/NCT03443024
Àø®ÄPK(°ò½uEASI25.5) ¹êÅç²Õ vs ¹ï·Ó组
EASI75 61% vs 24%(®t²§37%) IGA0,1 45% vs 15%(®t²§30%)
2.Lebrikizumab ph3
16¶g
Àø®ÄPK(°ò½uEASI???) ¹êÅç²Õ vs ¹ï·Ó组 (1)AD1 clinicaltrials.gov/ct2/show/results/NCT04146363
EASI75 59% vs 16%(®t²§43%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组¥§¡47% IGA0,1 43% vs 13%(®t²§30%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组47%~45%//¥§¡46%
(2)AD2 clinicaltrials.gov/ct2/show/results/NCT04178967
EASI75 51% vs 18%(®t²§33%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组¥§¡41% IGA0,1 33% vs 10%(®t²§22%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç²Õ 41%~33%//¥§¡37%
(3)Lebrikizumab¤QTCS Lebrikizumab ¤QTCS¡Ñ16¶g ¤T´Á¡A¦©°£¹ï·Ó组 @% IGA. 41-22=19 EASI75 70-42=28
3.ASLAN004 2b ´Á±æÈ °ò½u°²³]EASI25.5(¦PLeb. 2b) Àø®ÄPK ¹êÅç组vs ¹ï·Ó²Õ EASI75 73% vs 24%(®t²§49%) IGA0,1 57% vs 15%(®t²§42%)
4.Dupilumab ph3 www.nejm.org/doi/full/10.1
16¶g °ò½uEASI32.5 (1)SOLO1 EASI75 51%vs 15%(®t²§36%) IGA0,1 38%vs 10%(®t²§28%) (2)SOLO2 EASI75 44%vs 12%(®t²§32%) IGA0,1 36%vs 8%(®t²§28%)
(3)Dupilumab +TCS 16¶gvs 52¶g clinicaltrials.gov/ct2/show/results/NCT02260986
A.EASI75 QW//Q2W//¹ï·Ó²Õ--%
16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6
B.IGA0,1 QW//Q2W//¹ï·Ó²Õ--%
16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------(2017/10 ¤½§G)
5¡BLebrikizumab ¦y®p¾P°â预¦ô¥«³õ¤À§é®v45-150»õ¬ü¤¸¡C §¨Ó¤½¥q»{¬°¥i¬° ¤¤-««×AD²Ä¤@½uÃĪ«¡C (Ó¤H»{¬°Lebrikizumab 45»õ¬ü¤¸¦³¾÷·|//YµLASLSN004¤W¥«) Dupilumab ªºREGN ¤½¥q¦ô¦y®p¾P°â130»õ¼Ú¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/18 ¤U¤È 09:28:11
²Ä 5699 ½g¦^À³
|
³¯¤j¡A
¥H¤U¨PÄÝÓ¤H¦ôºâ¡A
ASLAN004 2b Á{§É clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3
°²³]65Ó¤¤¤ß¦b2022/08/30¶}¨S¬°³Ì«á ASLAN004 2b Á{§É¡A¹w¦ô¸Ñª¼¤é´Á¡G2023/02/15 ¹w¦ô³Ì«á¤@¦ì§¹¦¨²Ä¤@°wª`®g¤ê´Á¡G2022/1015
⋯⋯⋯¨Ì¾ÚLebrikizumab 2bÁ{§Éªº®Éµ{¸gÅç¡C
⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/7 ¤W¤È 08:44:19²Ä 5683 ½g¦^À³ clinicaltrials.gov/ct2/show/NCT03443024
Lebrikizumab 2b Á{§É°O¿ý
2018/8/23 ³Ì«á©Û¶Ò¤¤¤ß资®Æ§ó·s 2018/10/6¡]±À¦ô³Ì«á¤@¦ì±wªÌ¥´²Ä¤@针¤é´Á¡^ 2018/11/06 °±¤î©Û¶Ò¸ê®Æ§ó·s 2019/02/07 ¸Ñª¼ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/18 ¤U¤È 09:17:07
²Ä 5698 ½g¦^À³
|
³¯¤j¡A ¦¬®×§¹¦¨¯ÂÄݨ̾ÚLebrikizumab 2bÁ{§É±À¦ô¡A
°²³]8¤ë30¤é65Ó¤¤¤ß¬°³Ì«á¦¬®×¤¤¤ß¶}³]¡A¸g45¤Ñªº¿zÀË©Ò°ï¦ô¡]¦PLebrikizumab)
¤@¤Á¨Ì¤½¥q¤½¥¬¬°·Ç¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/18 ¤U¤È 08:13:18
²Ä 5697 ½g¦^À³
|
¤Ñ©R¤j
ASLAN004 2b¤w§¹¦¨³Ì«á¤@¦ì¦¬®×¡A¬O§_¦³¦@¦¬®×´X¤Hªº¸ê°T¶Ü
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/18 ¤U¤È 05:48:26
²Ä 5696 ½g¦^À³
|
¨Ì¾ÚLebrikizumab 2b ùµ{¸gÅç¡C ¦ô
ASLAN004 2b 2023¦~2¤ë15¤é¸Ñª¼¡C ³Ì«á¤@¦ì¤w¦¬®×§¹¦¨²Ä¤@°w¡C¦b2022¦~10¤ë15¤é
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/18 ¤U¤È 05:32:07
²Ä 5695 ½g¦^À³
|
www.aad.org/member/meetings-education/am23/faculty/abstracts
AAD 2023
³Ì·s¬ã¨s½×¤å¸`¿ý ³Ì«á¦¬¥ó¤é¡G2023/01/13
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/10/18 ¤U¤È 03:26:20
²Ä 5694 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j: °²Y004©ó112¦~2¤ë¤¤¸Ñª¼¥¿¦V¡A½Ð°Ý¨Ó±o¤Î°Ñ¥[·í¦~«×¬ü°ê¥Ö½§¾Ç·|(¨q¸ê®Æ)¶Ü? (¤µ(111)¦~¬ü°ê¥Ö½§¾Ç·|¬O¦b3¤ë25¤éÁ|¦æ).
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/16 ¤U¤È 03:35:04
²Ä 5693 ½g¦^À³
|
§¨Ó¤½¥q¦b9¤ë8¤éµoªí Lebrikizumb ¤T´Á52¶gÁ{§É³ø§i
¤½¥q¬Û«H ¥¼¨ÓLebrikizumab Y³Q®Öã¤W¥«¡A ¥i³Q¥Î©óªvÀø¤¤-««×ADªº²Ä¤@½uÃĪ«¡C
°ò©ó§Ú̦b¯SÀ³©Ê¥Öª¢Á{§É¸ÕÅ綵¥Ø¤¤Àò±oªºÃ°·¥B¨ã¦³Á{§É·N¸qªºµ²ªG¡A§Ú̬۫H¡A¦pªGÀò±o§åã¡Alebrikizumab ¥i¯à¦¨¬°¥Ö½§¬ìÂå¥Í¤Î¨ä³\¦h±w¦³¨Ï¤H°I®z¯gª¬ªº¤¤«×¦Ü««×¯e¯f±wªÌªº¤@½uªvÀøÃĪ«¨Ã´M¨D·sªºªvÀø¿ï¾Ü¡A¨Ã§ó³ßÅw¤£¨º»òÀWÁcªºµ¹ÃÄ¡A¡¨Â§¨Ó¤½¥q¥þ²y§K¬Ì¾Ç¶}µo©MÂå¾Ç¨Æ°È°ÆÁ`µô Lotus Mallbris Âå¾Ç³Õ¤h»¡ Based on the robust and clinically meaningful results from our clinical trial program in atopic dermatitis, we believe lebrikizumab, if approved, could become a first-line treatment for dermatologists and many of their patients with moderate-to-severe disease who suffer from debilitating symptoms and seek new treatment options and prefer less frequent dosing, said Lotus Mallbris, M.D., Ph.D., vice president of global immunology development and medical affairs at Lilly.
finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/15 ¤U¤È 02:24:50
²Ä 5692 ½g¦^À³
|
¨Ì¾ÚLebrikizumab ADªº«O¦u¾P°â¦ôºâ45»õ¬ü¤¸¡C
004 2b ¸Ñª¼¦p预´Á EASI 75 73% vs Leb. 2b 61% vs ¹ï·Ó组24%
IGA0,1 57% vs Leb. 2b 45% vs ¹ï·Ó组15%
°²³] °ò½uEASI 26-EASI 28
«h³æ¦bAD ³QASLAN004 ¨ÖÁʪ÷ÃB 约¬°2020¦~Leb.³Q¨Öª÷ÃB 11»õ¬ü¤¸x3¿=33»õ¬ü¤¸°_¸õ¡C(·í®É¦ô15»õ¬ü¤¸ªº¦y®p¾P°â¡K¡K¦©°£欧¬w区)
¨ä¥L¾AÀ³¯g=33/0.55-33=27»õ¬ü¤¸(2´Á§¹¦¨) ¥´Ó¹ï§éÁÙ¦³13.5»õ¬ü¤¸¡C
33+13.5=46.5»õ¬ü¤¸
¦ôp³Q¨ÖÁÊ»ù¦b45-50»õ¬ü¤¸¤§¶¡¡C
°²³]1000,000¤dªÑADR ªÑ¥»
¨CªÑ45-50¬ü¤¸¤§¶¡¡C
¶W¹L¤]¤£·N¥~¡C
¥H¤WÓ¤H¦ôºâ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/13 ¤U¤È 07:24:14
²Ä 5691 ½g¦^À³
|
ASLAN004 µ´¹ïÀu©óLebrikizumab ,¦]MOAÃö«Y¡AÀø®ÄµLªkéw¡A®É¦n®ÉÃa¡C
Lebrikizumab ¤x¦bý³Ý¡þCOPD ¤T´ÁÁ{§É¥¢±Ñ¡A¤x°±¤îÁ{§É¸ÕÅç¡C
Lebrikizumab ¶È¦bAD¥«¾P°â´N³Qµû¦ô45¡X150»õ¬ü¤¸ªº¦y®p¾P°â¡C ¤@¤@¤@¤@¤@
1¡ALebrikizumab ¤T´ÁÁ{§É vs¹ï·Ó²Õ
AD1. IGA. 43% vs 13%¦©°£¹ï·Ó²Õ ®t²§30%¡^ EASI75 59% vs 16%¡]¦©°£¹ï·Ó²Õ®t²§43%¡^
AD2 IGA 33%. Vs 11%(®t²§22%¡^ EASI75 51% vs 18%(®t²§33%¡^ ¤@¤@¤@¤@¤@
2¡ADupilumab ¤T´Á Solo1 IGA 38% vs 10%¡]®t²§28%¡^ EASI 75 51% vs 15%¡]®t²§36%¡^ Solo2 IGA 36% vs 8%(®t²§28%¡^ EASI75 44% vs 12%(®t²§32%¡^ ¤@¤@¤@¤@ 3¡AASLAN004 2b ¥Ø¼ÐÀø®Ä
IGA 53% vs 15%(®t²§38%¡^ EASI75 73% vs 24%(®t²§49%¡^
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/13 ¤U¤È 06:57:57
²Ä 5690 ½g¦^À³
|
Lebrikizumab ¦y®p¾P°â45»õ¬ü¤¸¤@¤@¤@¬ü°ê¤ÀªR®vEdmund Ingham¦ô
³Ì°ª¹w´ú½æ150»õ¬ü¤¸¡C
2022/09/28 ¤å³¹¦p¤U
I am more optimistic on sales of 2 newcomers however in Lebrikizumab and Mirikizumab.
Lebrikizumab has been compared to Sanofi¡¦s Dupixent, itself forecast to achieve peak sales of ~$15bn by some optimistic analysts, and has even outperformed Dupixent in some studies, so perhaps I am being too conservative forecasting peak sales of just $4.5bn.
Lebrikizumab ©M Mirikizumab ªº 2 ¦W·sÃĪº¾P°â§ó¬°¼ÖÆ[¡C
Lebrikizumab »PÁɿյ᪺ Dupixent ¶i¦æ¤F¤ñ¸û¡A¤@¨Ç¼ÖÆ[ªº¤ÀªR®v¹wp¨ä¾P°âÃB®pȱN¹F¨ì¬ù 150 »õ¬ü¤¸¡A¦b¤@¨Ç¬ã¨s¤¤¬Æ¦Ü¶W¹L¤F Dupixent¡A©Ò¥H¤]³\§Ú¹L©ó«O¦u¦a¹w´ú®pȾP°âÃB¶È¬° 45 »õ¬ü¤¸¡C
Eli Lilly: Valuation Feels Impossibly High - Don¡¦t Board This Hype Train
Sep. 28, 2022 12:26 PM ETEli Lilly and Company (LLY)9 Comments 1 Like
Edmund Ingham
seekingalpha.com/article/4543610-eli-lilly-valuation-feels-high-dont-board-the-hype-train
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/13 ¤U¤È 03:19:34
²Ä 5689 ½g¦^À³
|
©MDupilumab ¦³¥i¯à±M§Q°ÝÃD¡AÃø¦b2037¦~«e¬ü°ê¤W¥«¡C ¤¤°ê¥Ó½Ð´X¦~«á¤W¥«¦³¥i¯à¡A
¤¤°ê2´Á ¥Dn«ü¼ÐIGA 0,1 ¶È30.3%°¾§C.
¬Q¤ÑCNTBªÑ»ù¤S§C©ó1¬ü¤¸¡A¦¬0.95¬ü¤¸¡AÃø¦b¨Ìp¹º¦b¬ü°ê¥«³õ¶Ò¶°3»õ¬ü¤¸°µ¤T´ÁADÁ{§É¡C
CNTB 2023/10/04 ¤½§G CBP201 ¤¤°ê2 ´Á¤¤¤@««×ADÁ{§É¸Ñª¼³ø§i October 4, 2022
¤@¤@¤@
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China finance.yahoo.com/news/correcting-replacing-connect-biopharma-reports-125600879.html
All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD
Safety and tolerability results for CBP-201 consistent with targeting the IL-4R£\ pathway
Data support advancing the regulatory discussions with the CDE for submitting an NDA in China
¹êÅç²Õ vs. ¹ï·Ó²Õ ¥Dn«ü¼ÐIGA0¡A1 30.3% vs 7.5%(¦©°£¹ï·Ó²Õ«á22.8%//Dupilumab¤T´Á¬°28%¡]38%vs 10%¡^¡^ ¦¸n«ü¼Ð EASI75 62.9% vs 23.4%¡]¦©°£¹ï·Ó²Õ«á 39.5%//dupilumab ¤T´Á¬°36%¡]51%-15%) ) EASI50 83.1%vs 43.1% EASI90 35.8% vs 6.3%
The primary endpoint of IGA of 0 or 1 (¡§clear¡¨ or ¡§almost clear¡¨) with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group (p < 0.001).
CBP-201 also met key secondary endpoints, including 83.1%, 62.9% and 35.8% of patients achieving a 50%, 75%, 90% reduction in the Eczema Area and Severity Index score (EASI-50, EASI-75, EASI-90) from baseline compared to 41.1%, 23.4% and 6.3% for the placebo group (p < 0.001), respectively. Significant improvement in pruritus with 35.0% of patients experiencing a reduction of 4 or greater on the Peak Pruritus-Numerical Rating Scale (PP-NRS) compared to 9.6% for placebo (p < 0.001).
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China clinicaltrials.gov/ct2/show/NCT05017480?term=Cbp201&draw=2&rank=2
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/10/13 ¤W¤È 08:51:20
²Ä 5688 ½g¦^À³
|
Tang Capital Management LLC ³Ìªñ«Å¥¬¦¬ÁÊ ASLAN Pharmaceuticals Limited¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^ªº·sªÑ¥÷¡C¾÷ºc§ë¸êªÌ³q¹LÁʶR227¸UªÑ¡A±N¨ä¦bÂåÀø«O°·¤½¥qªºªÑÅv¼W¥[69.04%¦Ü555¸UªÑ¡C³o¶µ·s§ë¸ê²{¦b¨Ï¨ä«ùªÑ¤ñ¨Ò¹F¨ì 7.97%¡A¥Ø«e¦ôȬ° 344 ¸U¬ü¤¸¡C¦¹¥~¡AMillennium Management LLC ¼W«ù 43949.0 ªÑ¦Ü 161 ¸UªÑ¡CRenaissance Technologies LLC ¤w±N¨äÀY¤o¼W¥[ 574.07% ©Î 41 ¸UªÑ¡A¦Ü 48 ¸UªÑ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/10/12 ¤W¤È 10:43:02
²Ä 5687 ½g¦^À³
|
§Æ±æÁÙ¬O·|¦³¥¿¦V´Á¤¤¼Æ¾Ú¡A³o¼Ë¹ï¦Ñ·à¤Í¤ñ¸û¦n~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/11 ¤W¤È 10:33:26
²Ä 5686 ½g¦^À³
|
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c
10¤ë7¤é³Ì·sªº¤½¥q²³ø
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/11 ¤W¤È 10:28:02
²Ä 5685 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3
ASLAN004 2b Á{§É¡A¹w¦ô¸Ñª¼¤é´Á¡G2023/02/15
⋯⋯⋯¨Ì¾ÚLebrikizumab 2bÁ{§Éªº®Éµ{¸gÅç¡C ¦A¨Ó11¤ë¤¤¦¯·|«Å¥¬¡A¤w§¹¦¨³Ì«á¤@¦ì©Û¶Ò¡A¦Ó°±¤î©Û¶Ò¡C
¦p¦¹ªº³W¹º¡AÀ³¸Ó¤£·|¦³´Á¤¤³ø§i¡C
⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/10/7 ¤W¤È 08:44:19²Ä 5683 ½g¦^À³ clinicaltrials.gov/ct2/show/NCT03443024
Lebrikizumab 2b Á{§É°O¿ý
2018/8/23 ³Ì«á©Û¶Ò¤¤¤ß资®Æ§ó·s 2018/11/06 °±¤î©Û¶Ò 2019/02/07 ¸Ñª¼ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªü¦Ì¤ÚìÂÎ10145310 |
µoªí®É¶¡:2022/10/10 ¤W¤È 12:02:33
²Ä 5684 ½g¦^À³
|
www.nature.com/articles/s41573-021-00266-6.pdf ¤µ¦~ªì¦³¤H¾ã²zªº¤å³¹ ¸Ì±¦³´£¨ìASLN004ªº³¡¤À ASLAN004 is a fully humanized antibody directed against IL-13R£\1, thereby blocking the binding of IL-4 and IL-13 on the type II receptor (IL-4R£\/IL-13R£\1). Owing to the more selective binding compared with dupilumab, ASLAN004 may provide the option of a low-dose regimen and a better safety profile. An interim data analysis from a phase Ib study showed that the com- pound is well tolerated and provided promising efficacy data, with 67% of the patients achieving EASI75 versus 0% in the placebo group |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 901 ~ 1000 «h¦^ÂÐ >> |